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1 Summary
Classical chemotherapy is often accompanied by severe adverse effects and new combination
therapy options to circumvent this problem are still needed. Actin binding substances have
shown promising results in different experimental setups but have not made it into the clinics
yet. The proposed role of actin in DNA damage repair, however, makes actin binders potential
combination partners with DNA damage inducing chemotherapeutics like doxorubicin. In this
study, actin binding substances, such as the actin polymerizer jasplakinolide and the depoly-
merizer latrunculin B (LB), were applied to investigate the mechanisms of the proposed role of
actin in nuclear DNA double strand break (DSB) repair pathways and to assess whether the
application of actin binders is feasible for combination cancer therapy.
DSB induction by doxorubicin treatment led to a reduction of a mobile nuclear actin fraction
and to an increase in polymerized actin in the nucleus, suggesting that the polymerization state
of nuclear actin plays a crucial role in DNA damage signalling. DSB repair strongly depended
on the maintenance of the actin equilibrium and actin manipulation inhibited DSB repair by
influencing specific signalling cascades in distinctive DSB repair pathways. During homology
directed repair (HDR) and single strand annealing (SSA), actin binders affected the recruitment
of replication protein A (RPA) to the site of DNA damage, a process that is essential for the
induction of both pathways. RPA was bound to nuclear actin under control conditions and
released after damage induction, indicating that actin is directly involved in the recruitment
of this repair factor. Furthermore, during non-homologous end joining (NHEJ), actin binders
reduced activating phosphorylation of DNA-PK. Functionally, synergistic effects of low dose
combination therapy of Doxo and LB on proliferation in different cancer cell lines could be
demonstrated in vitro, and these effects could be linked to an increased DNA damage level in
tumor cells in vivo.
In summary, these findings imply a direct involvement of actin in nuclear DNA damage repair
mechanisms and propose a possible application of actin binding substances for combination
therapy with DNA damage inducing agents.
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2 Introduction
2.1 The role of DNA damage induction and repair in cancer therapy
2.1.1 Cancer incidence and general treatment strategies
Cancer is a multifactorial malignant disease and is one of the leading causes for death worldwide
with lung, liver, colorectal and breast cancer among the most frequent cancer types [1–3]. The
generation of malignant tumors happens during a multistep process in which healthy cells acquire
distinctive capabilities that help them become tumorigenic. These capabilities that are required
for tumorigenesis were termed hallmarks of cancer. They include, among others, the increase in
cell proliferation due to the enabling of replicative immortality and the escape from cell death in-
duction and growth suppression, as well as the activation of angiogenesis, invasion and metastasis
[4, 5]. Targeting the above mentioned hallmarks is considered a promising strategy for tumor
therapy. Classical chemotherapeutics, like the DNA damage inducing agent doxorubicin or the
cytoskeleton targeting paclitaxel, mainly address the first two mentioned characteristics, namely
increased cell proliferation and evasion of cell death. Doxorubicin causes cell cycle arrest and
cell death by inducing high levels of DNA damage, whereas paclitaxel attacks the microtubule
system. As highly proliferative cells, such as cancer cells, strongly depend on functional DNA
replication and cytoskeleton functions, both agents can successfully be used for cancer therapy
[6, 7]. However, high proliferation rates are not exclusive to cancer cells and neither the DNA
nor the cytoskeleton represent tumor tissue specific targets. Treatment with these chemothera-
peutics leads therefore to severe side effects [7, 8]. To reduce unwanted side effects during cancer
therapy, more selective agents were designed. To give one example, the development of kinase
inhibitors was based on the idea to inhibit signalling pathways that are hyperactivated in can-
cer due to tumor specific mutations [9]. Veramufenib for instance specifically inhibits mutated
BRAF in melanoma and showed very promising results in clinical trials. However, resistance de-
veloped after only a few months, probably because of the very high specificity of this approach
[10]. In general, initially efficient monotherapies often fail after a prolonged time period due to
the development of resistances [11]. In order to evolve towards a malignant status, cancer cells
have to acquire modifications in more than one of the above mentioned processes [5]. Targeting
not only one but several of those hallmarks by combination therapy represents a strategy to on
the one hand increase the efficacy of the administered drugs and thereby reduce side effects and
on the other hand prevent rapid development of treatment resistances.
As the number of cancer patients is still expected to grow [3] and the above mentioned
problems that arise during cancer therapy are often still not solved, the need to develop new
strategies remains. The formulation of new combination therapies offers a promising approach.
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2.1.2 Induction of DNA damage by the chemotherapeutic doxorubicin
Doxorubicin (Doxo), also called adriamycin, belongs to the class of anthracyclines and was first
isolated as a metabolite of Streptamyces peucetius var. caesiues [12] (see Fig. 1).
Figure 1: Chemical structure of doxorubicin [13].
Doxo binds to DNA and topoisomerase 2 (top2) isoenzymes. The formation of top2-doxo
complexes at the DNA induces DNA double strand breaks (DSBs) and thereby inhibits DNA
replication and promotes cell cycle arrest and apoptosis [6, 14–16]. Additionally, Doxo is involved
in the generation of reactive oxygen species (ROS) and thus increases oxidative stress in cells [8].
It is nowadays widely used in the clinics for chemotherapeutic cancer treatment, such as breast,
lung and ovary carcinomas [17]. However, due to its short half-life in the blood circulation and its
extensive non-selective tissue distribution, treatment with Doxo is accompanied with severe side
effects. Even though Doxo proved to be highly efficient in cancer therapy, it leads to both acute
and delayed cardiotoxicity as cardiomyocytes are especially sensitive to Doxo induced oxidative
stress. As a consequence, cancer patients that underwent anthracycline chemotherapy carry the
risk for early cardiovascular morbidity [18–20].
Although Doxo shows dose-limitations due to its organ toxicity, it is still considered to be
one of the most potent chemotherapeutics. It is therefore a promising candidate for combination
therapy to make use of its anti-tumoral potential and even further increase its efficacy while
reducing unwanted secondary effects. A rather new idea is to exploit dysregulated DNA damage
repair signalling for cancer therapy. The FDA approval of the first DNA repair inhibitor olaparib
[21] showed that DNA repair inhibition is indeed feasible for cancer therapy. The addition of
DNA repair factor inhibitors to DNA damage inducing chemotherapeutics, however, represents
a so far uninvestigated approach. Further extensive research is therefore needed to evaluate in
detail if the inhibition of a potential tumor suppressive process such as DNA damage repair can
be used for cancer therapy in combination with DNA damage inducing agents.
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2.1.3 DNA double strand break repair pathways
The DNA damage response (DDR) describes the collectivity of all processes that are directly
involved in the repair of damaged DNA and also includes all associated pathways that are ac-
tivated. After sensing of damages DNA, cell cycle arrest ensures that the cell gets enough time
to repair the damage, whereas cell death is induced if the extent of DNA damage is too high to
be repaired in time. Depending on the type of damage, different repair pathways are triggered
[22, 23]. In this work, mainly the double strand break of the DNA and its associated repair path-
ways will be explained in detail, since it is inflicted by treatment of cells with chemotherapeutics
such as doxorubicin and represents the most deleterious type of damage.
Double strand breaks are sensed by MRN complex, which is composed of the three members
Mre11, Rad50 and Nbs1. MRN is involved in early DNA repair processes by its recruitment to
the site of damage followed by the phosphorylation and activation of its numerous substrates
(see Fig. 2). The activation of MRN not only starts signalling pathways directly necessary for
DNA repair but also regulates associated processes such as cell cycle checkpoint activation.
MRN is therefore considered to be one of the key players of DSB repair in the cell (reviewed
in [24, 25]). One important substrate of the MRN complex is ATM which is activated upon
DSB induction and plays a fundamental role in DSB repair [24, 26]. The ATM-Chk2 pathway
is not only involved in Rad51-dependent DNA repair, but also in Cdc25-dependent cell cycle
arrest and p53-mediated apoptosis induction (see Fig. 2). ATM furthermore phosphorylates the
histone H2AX at Ser139 [27], which leads to the recruitment of the nuclear protein MDC1, a
multidomain scaffolding protein that is important for many functions of phosphorylated H2AX
(yH2AX) during DSB repair [28, 29]. MDC1 amplifies the DSB response as it recruits MRN and
retains ATM associated to MRN, resulting in its prolonged activation [30, 31]. Phosphorylation
of H2AX is thus involved in early DSB signalling. Detection of yH2AX foci is often used as a
biomarker for damaged DNA as phosphorylation of H2AX represents a very sensitive indicator
of the presence of DSBs [32, 33].
Double strand breaks can be repaired by four different repair pathways and the choice depends
primarily on the cell cycle state of the cell (see Fig. 3). Non-homologous end joining (NHEJ)
describes the annealing of blunt DNA ends which occurs throughout the cell cycle, but domi-
nantly in GO/G1 and G2, and functions independently of sequence homology. On the contrary,
the other three pathways, homology-directed repair (HDR), single strand annealing (SSA) and
alternative end joining (alt-EJ), are homology-based repair pathways and depend to different
extents on DNA end resection, i.e. the processing of DNA adjacent to the DSB to generate
ssDNA (reviewed in [34, 35]).
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Figure 2: The MRN-ATM-yH2AX pathway in double strand break (DSB) repair (simplified). The
MRN complex is formed upon DSB induction and is responsible for the activation of signalling path-
ways involved in DNA repair and induction of apoptosis and cell cycle arrest. MRN phosphorylates
ATM which leads to the activation of its kinase activity. ATM phosphorylates e.g. Chk2, H2AX and
p53.
During NHEJ, the Ku70/80 heterodimer (Ku) is the first protein complex that is recruited
to free DNA ends that appear upon DSB induction. The resulting Ku-DNA complex forms the
basis for the recruitment of nucleases, polymerase and ligases that are required for the joining of
both adjacent DNA ends of the DSB [36, 37]. Binding of Ku to DNA presumably leads to con-
formational changes that allow additional binding of DNA-PKcs (catalytical subunit) [38, 39].
The DNA dependent protein kinase (DNA-PK) is thus formed by the binding of its catalytical
subunit to DNA-bound Ku, resulting in its activation. Activated DNA-PK extensively phos-
phorylates itself but also many other targets involved in NHEJ [40, 41]. One important target
of DNA-PK is the endonuclease Artemis. If two DNA ends are unsuitable for direct ligation,
for example due to incompatible 3’ or 5’ overhangs, Artemis can be recruited in complex with
DNA-PKcs and upon autophosphorylation of DNA-PK is activated by it and gains its endonu-
clease activity [42]. Endo- and exonuclease activities are needed for limited DNA end resection
(<5 nucleotides) to ensure that the two DNA ends are compatible and Artemis seems to be the
primary nuclease for that [43]. For example, Artemis removes the incompatible 3’ and 5’ DNA
overhangs in order to create DNA ends that can be ligated later by the XRCC4-DNA ligase
IV complex [37]. Ku catalyzes DNA ligation, i.e. the bridging between two DNA ends, as it
promotes the binding of XRCC4-DNA ligase to the DNA ends [44–46]. Ku also interacts with
polymerases µ and λ which promote ligation of DNA ends [37, 47]. The two subunits of the
DNA-PK - Ku and DNA-PKcs - are thus key players in NHEJ signalling, since they regulate
many involved factors.
As mentioned above, the other DSB repair pathways depend on DNA end resection, i.e. the
nucleolytic degradation of DNA ends. End resection results in ssDNA sections which are required
for recruitment of specific repair proteins involved in homology based repair pathways [48, 49].
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Figure 3: Distinct pathways for DNA double strand break repair. Dependent on the cell cycle state,
DNA double strand breaks (DSB) will be repaired by non-homologous end joining (NHEJ), alternative
end joining (Alt-EJ), homology derived repair (HDR) or single strand annealing (SSA).
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The above mentioned MRN complex plays a crucial role in the induction of end resection, for
example due to the exo- and endonuclease activities of Mre11 [50, 51]. Together with its interac-
tion partner CtIP (C-terminal binding protein 1 (CtBP1) interacting protein) the MRN complex
mediates the first step of end resection to generate short ssDNA sections [52]. The limited end
resection by MRN and CtIP is sufficient for the activation of alt-EJ, which utilizes PARP-1 me-
diated annealing at short homologous DNA sequences (<10bp = microhomologies). Nucleases,
polymerases as well as the DNA ligase III complex can be involved in alt-EJ, depending on how
it is orchestrated [34].
In the second step of end resection, termed ’extensive resection’, EXO1 (exonuclease 1) and
DNA2 endonuclease/-BLM helicase are recruited to generate longer ssDNA tails [52] that are
required for the binding of replication protein A (RPA). RPA is a heterotrimer composed of the
RPA70 (=RPA-1), RPA32 (=RPA-2) and RPA14 (=RPA-3) subunits [53] and its binding to
ssDNA is crucial for the initiation of both HDR and SSA. During HDR, which can only occur if
a template, i.e. the sister chromatid, is available, BRCA2 mediates RPA replacement by Rad51
[54]. Coating of the ssDNA with Rad51 is required for strand invasion of the intact homologous
region on the sister chromatid which serves as the template for accurate repair [55, 56]. The
DNA strand is then extended by a DNA polymerase which leads to the creation of a D-loop.
After D-loop creation, the error is repaired either by the formation of a Holliday junction or
is completed via noncrossover products without Holliday junction formation (termed synthesis-
dependent strand annealing pathway) [57].
The second RPA dependent pathways is SSA which is not based on sister chromatid exchange
but uses homologous repeat sequences that flank the DSB. Rad52 binds to the ssDNA-RPA
complex and together they facilitate both the alignment and the annealing of homologies around
the break [55, 58, 59]. ERCC1 forms a complex with XPF that cleaves 3’ssDNA tails upon
annealing, gaps are filled by DNA polymerases and the activation of DNA ligase completes SSA
[60].
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2.2 The actin cytoskeleton - a potential target?
2.2.1 Actin structure and function in cytoplasm and nucleus
The cytoskeleton of the cell is a dynamic polymer network which is comprised of three main
components (reviewed in [61]): the microtubule system [62], intermediate filaments [63] and mi-
crofilaments (also known as the actin cytoskeleton) [64].
Actin, a 42 kDa structural protein, is highly conserved through all species and belongs to
the most abundant proteins - almost all eukaryotic cells harbour genes for actin. Actin can be
found in both muscle and non-muscle cells [65, 66] and in mammals in six different isoforms,
αcardiac-, αskeletal-, αskeletal-, βcyto-, γcyto- and γsmooth-actin (reviewed in [67]). In general the
actin cytoskeleton is essential for the mechanical structure and motility of a cell and thus plays
a role in many physiological functions [68]. The actin cytoskeleton is involved in the forma-
tion of cellular structures like lamellipodia, stress fibers and focal adhesions which are needed
for cell movement and migration [69]. Additionally, actin is crucial for cell division and pro-
liferation as the functional separation of two daughter cells during cytokinesis of mammalian
cells depends on the contractile ring of actin filaments. Furthermore, eukaryotic cells transport
organelles along the actin cytoskeleton making it also an important transport system in cells [68].
Actin exists in two states in the cell, monomeric G-actin and polymerized, filamental F-actin.
F-actin is formed in a three steps process which includes a nucleation, an elongation and a
steady state phase (Fig. 4). During the first phase, three to four G-actin monomers aggregate
into unstable oligomers (nuclei). The addition of further actin monomers leads in the next phase
to the rapid elongation of the nucleus into a filament. The F-actin filament will grow until a
steady state is obtained in which an exchange of actin monomers is still observed, but with-
out any change in the total mass of F-actin filaments (described in [70]). Actin filaments are
asymetric, also termed polar, with a pointed (-) end where actin monomers can be dissociated
(depolymerization of the actin filament), preferably when bound to ADP, and a barbed (+)
end at which ATP-bound actin monomers can be added (polymerization of actin) [71]. Both
poly- and depolymerization processes of actin are tightly controlled by on the one hand proteins
that bind to monomeric G-actin and on the other hand proteins that bind to the barbed end of
F-actin filaments (reviewed in [71, 72]). Up to now more than 100 actin binding proteins (ABPs)
are known to be directly involved in the regulation of the dynamic process of actin polymeriza-
tion [68]. To name only a few, gelsolin and ADF/cofilin are involved in the actin turnover by
promoting actin filament disassembly [73, 74], whereas profilin and the Arp2/3 complex play a
central role in filament assembly (reviewed in [71, 75, 76]). Arp2/3 complex e.g. is activated by
WASP family proteins and catalyses nucleation of F-actin filaments with free barbed ends [71].
Polymerization of actin is therefore a very dynamic process depending on the needs of the cell.
For a long time actin function has mostly been associated with the cytoplasm, but since its
discovery in the nucleus in 1969 [77], an increasing number of studies suggests important nuclear
functions of actin. In contrast to cytoplasmic actin, nuclear actin is believed to exist mainly as
monomers or oligomers under physiological conditions [78], but polymerization of nuclear actin
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Figure 4: States of actin in the cell. Three actin monomers (G-actin) form a nucleus which is the basis for
the formation of filamental F-actin during the elongation process until a tightly regulated steady state
is obtained. In the cell F-actin is mainly polymerized at the barbed end (+) and depolymerized at the
pointed end (-).
seems to occur as a stress response e.g upon heat shock or DNA damage induction [79, 80].
Polymerized actin in the nucleus was first described by McDonald et al. [81] and actin nucle-
ators were found later on in the nucleus as well (reviewed in [82]), strengthening the assumption
that actin filament assembly also happens in the nucleus. Moreover, different mechanisms of
active actin transport from and to the nucleus have been described. In general, nucleocytoplas-
mic traffic of proteins occurs via nuclear pores, either by passive diffusion (<40kDa) or active
transport receptors (>40kDa) [83]. Actin does not harbor a NLS sequence and cannot pass the
nuclear pores by passive diffusion and is thereby considered to be dependent on one or more
transport systems. ABPs, such as cofilin, harbor NLS motifs and might therefore play a role in
the transport of actin from or to the nucleus. Cofilin and importin-9 were shown to be important
for the import of actin to the nucleus [80, 84, 85], whereas exportin-6 was found to be responsible
for the export of profilin-bound actin [86]. In addition, actin harbors two NES (nuclear export
sequence) sequences which are necessary for the actin export via exportin-1 [87]. Actin is con-
sidered to be involved in different nuclear mechanisms. Actin is for example not only responsible
for the mechanical integrity of the cytoplasm but also of the nucleus, as the nuclear matrix was
found to mainly consist of actin [88]. Additionally, actin was proposed to function in chromatin
remodeling and modifying mechanisms, as it is part of chromatin remodeling complexes during
transcriptional activation and in histone acetyl transferase complexes (chromatin modifiers) (re-
viewed in [89, 90]). Along these lines, actin seems to be important for the regulation of RNA
polymerase II-mediated transcription [91]. Several studies have been published that propose an
involvement of nuclear actin in DNA damage repair signalling as well (see 2.2.4).
2.2.2 Targeting actin with actin binding substances
The state of actin can be manipulated by two distinct classes of actin binding substances (Fig.
5 and 6). Polymerizers, such as jasplakinolide, chondramides and miuraenamides promote poly-
merization (or aggregation) of actin and therefore increase the F-actin pool in the cell. On the
contrary, depolymerizers, such as latrunculin B and chivosazole reduce the appearance of fila-
mental actin and increase the G-actin pool.
Among the actin polymerizers, jasplakinolide (Jaspla) was first described in 1988 as an anti-
fungal agent isolated from the soft-bodied sponge Jaspis species (Astrophorida, Jaspidae) [92].
Jaspla is a potent inducer of actin polymerization and binds with phalloidin competitively to
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Figure 5: Targeting of actin by actin binding substances. The state of actin can be manipulated by two
distinct classes of actin binding substances. Polymerizers promote actin polymerization and thereby
increase the F-actin pool in the cell. Among the polymerizers, jasplakinolide binds to F-actin and
impairs depolymerization of actin at the (-) end. Depolymerizers, on the contrary, decrease the F-
actin pool by preventing polymerization of actin. For example, Latrunculin B binds to G-actin and
impairs addition of actin monomers to an existing actin filament.
F-actin, resulting in stabilized filamental actin that is resistent to depolymerization in vitro [93].
Chondramides, first isolated from the myxobacterial strain Chondromyces crocatus, are struc-
turally very close to Jaspla and act in a similar way as they also bind to the actin binding site
of phalloidin [94, 95]. Like Jaspla, chondramides stabilize existing actin filaments and reduce
the number of physiological actin stress fibers in the cell by unphysiological actin aggregation
[95, 96]. Miuraenamides were first isolated from the myxobacterial strain SMH-27-4 as potential
antibiotic agents [97] and miuraenamide A (Miu) was later identified as another actin binding
and polymerizing substance [98]. Miu can now be obtained by full synthesis [99, 100].
As mentioned above, actin can also be manipulated in the opposite way, by preventing actin
polymerization and thereby increasing the G-actin pool. Both toxins latrunculin A and B, pu-
rified from two Latrunculia magnifica species (marine sponges), were one of the first identified
actin depolymerizers. Effects of latrunculins on microfilament organization were found to be pro-
nounced, but reversable, and specific to actin (and not microtubules) [101]. Four years later it
could be shown that the effect of latrunculin on the actin organization is caused by a direct bind-
ing of latrunculin to actin monomers which leads to an impairment of actin polymerization [102].
Total synthesis of latrunculin B (LB) has been possible for over 20 years [103] and it is still used
for research as a classical actin depolymerizer. Chivosazoles are less known and characterized
actin binding substances, isolated from the culture broth of the secondary metabolite-producing
myxobacteria strain So ce56 (S. cellulosum) [104]. Chivosazole A and F show strong effects
on the actin cytoskeleton of cells, comparable to latrunculins. In vitro it could be shown that
chivosazoles not only inhibit actin polymerization but also cause depolymerization of already
existing actin filaments [105]. Chivosazoles are not as widely used yet, but provide new tools for
actin manipulation and investigation.
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Figure 6: Structures of actin binding substances. A Polymerizers. Jasplakinolide [95], Chondramides
[95], Miuraenamides [97]. B Depolymerizers. Latrunculin B [106], Chivosazole A [104].
2.2.3 The cytoskeleton as a chemotherapeutic target - potential application of
actin binding substances
Actin is required for cellular functions like proliferation and migration, processes that are abso-
lutely necessary for the development of malignant and metastatic cancers [5]. Actin represents
thus a promising target for cancer therapy, a strategy which is not applied in the clinics yet,
mainly due to feared severe side effects.
Nevertheless, targeting of actin has been suggested as a potential approach for cancer treat-
ment by different groups, as actin manipulation exhibits anti-proliferative and anti-metastatic
characteristics on tumor cells. Anti-tumor activities of Jaspla could be shown in vitro in three
prostate carcinoma cell lines and in vivo in Lewis lung carcinoma and prostate carcinoma
xenografts. Moreover, application of Jaspla showed additive effects when combined with ra-
diotherapy in different experimental approaches [107, 108]. In our group, chondramide showed
anti-metastatic potential in migration and invasion assays in vitro and inhibited metastasis to
the lungs in a breast cancer model in vivo, which was linked to the inhibition of the cellular con-
tractility [109]. Furthermore, chondramide induced caspase dependent apoptosis in breast cancer
cell lines, whereas non-tumor breast epithelial cells were found to be less sensitive to chondramide
treatment [110]. Although latrunculins and chivosazoles act the opposite way, they nevertheless
have been reported to exhibit chemotherapeutic potential. In human gastric adenocarcinoma
cells (MKN45, NUGC-4), latrunculin A treatment induced caspase dependent apoptosis in vitro
and led to improved survival rates of mice bearing MKN45 or NUGC-4 tumors [111]. Addition-
ally, latrunculin A was reported to enhance radiosensitivity in cancer cells in colony formation
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assays and to impair yH2AX-formation upon radiation [112]. Furthermore, chivosazoles A and
F both showed high anti-proliferative activity in human cancer cell lines [105].
Although actin binding substances showed anti-cancer characteristics in different experimental
setups, until now, the application of actin binding substances as a potential cancer therapy
approach has not been studied in detail and is still far from clinical use. The above mentioned
actin binding substances are nevertheless promising candidates for further investigations and
preclinical development.
2.2.4 Impact of actin reorganization on nuclear DNA damage signalling pathways
The presence of damaged DNA induces a great diversity of signalling pathways in the cell and
actin dynamics seem to influence the response to DNA damage on multiple levels. Polymeriza-
tion of actin has been reported to be induced by DNA strand breaks and to be required for DSB
repair.
It has been suggested by several groups that nuclear actin may play a direct role in DNA
damage (repair) signalling. One study showed that a reduction of the nuclear actin pool by
knockdown of the nuclear actin import factor IPO9 led to an increase in the number of DSBs
after treatment with methyl methanesulfonate (MMS). Knockdown of the export factor XPO6,
and the consequent increase of the nuclear actin pool, did not show any significant effects on
DBSs after treatment [79]. Thus, the availability of actin in the nucleus seems to be important for
DNA damage repair processes. Furthermore, nuclear actin filament formation could be detected
upon DNA damage induction by application of specific fluorescent probes that enable visualiza-
tion of actin in the nucleus [79]. To conclude, not only the existence of sufficient nuclear actin
but its polymerization was proposed to be required for efficient DSB repair [79, 113]. Actin bind-
ing substances have been applied by several groups in order to investigate the role of different
actin states in DNA damage repair processes. Latrunculin treatment of cells prior to irradiation
impaired DNA damage repair. The disruption of actin polymerization by latrunculin has been
shown to interfere with the chromatin association of different DSB repair proteins (Ku80, Mre11,
Nbs1, ATM, Chk2) upon DNA strand break in subcellular fractions [113]. Polymeric actin was
found to be bound to Ku in a F-actin pulldown assay and polymerization of actin was therefore
considered to be essential for DSB repair [113]. In pulldown assays of HeLa nuclear extracts,
in addition to Ku, other DNA damage repair factors, like RPA-3 and DNA-PKcs, have been
suggested as potential actin binding proteins. However, the proposed interactions have not been
experimentally validated in this study [114]. If disruption of polymerized actin has an effect
on the phosphorylation of the most commonly used DNA damage marker H2AX is not clear,
as different groups published opposing results [112, 113]. Moreover, nuclear F-actin seems to
participate in the binding of p53 to the nuclear matrix and p53 binding to F-actin was increased
upon DNA damage induction [115].
In addition to direct functions of nuclear actin on DNA damage repair, indirect effects of actin
on nuclear processes have been published. F-actin can directly bind to p53 [116] and inhibits its
nuclear import by retaining it in the cytoplasm [117], which allows the cell to repair the damage
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before cell cycle arrest or apoptosis are started. On the other hand, the G-actin binding protein
JMY is released upon actin polymerization following DNA damage induction and can now enter
the nucleus to enhance transcriptional activity by directly binding to p53 [118, 119].
The above mentioned examples show that the regulation of DNA damage induced mechanisms
by reorganization of actin, both in the cytoplasm and in the nucleus, is very complex and has
to be tightly regulated and is still far from being completely understood.
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2.3 Aim of the study
Classical chemotherapeutics are potent agents against cancer, but due to their insufficient speci-
ficity, treatment is often accompanied by severe side effects. Combination therapy is a promising
concept to make use of the anti-tumor characteristics of chemotherapy, while reducing substance
concentrations and unwanted secondary effects. One approach is to combine DNA damage induc-
ing agents with additional DNA repair inhibitors. Hovewer, most of the substances investigated
for this purpose have not (yet) surpassed preclinical trials and novel combination therapy formu-
lations are still needed. Actin binding compounds are still not used in the clinics, but represent
a promising tool as malignant cells are often especially dependent on cytoskeletal functions. In
addition, an involvement of actin in nuclear DNA damage processes has been suggested, but is
not yet well understood. Nevertheless, a potential requirement of functional actin in DNA repair
makes it a possible candidate for combination therapy with DNA damaging agents.
The aim of this study was on the one hand to uncover the underlying mechanisms behind
the proposed involvement of actin in nuclear processes during DNA double strand repair and
on the other hand evaluate the application of actin binding substances in combination with the
chemotherapeutic doxorubicin as a novel strategy for cancer therapy.
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3.1 Materials
3.1.1 Technical equipment
Table 1
Product Supplier
BIO-RAD PowerPac Basic Electrophoresis Power
Supply
Bio-Rad Laboratories, Munich, Germany
ChemiDocTMTouch Imaging System Bio-Rad Laboratories, Munich, Germany
FACSCantoTMII BD Biosciences, Heidelberg, Germany
FACSCaliburTM BD Biosciences, Heidelberg, Germany
Heated Plate for 1 Chamber in Multi-Well Format Ibidi, Martinsread
Heated Plate universal fit Ibidi, Martinsread
HeracellTM150, CO2 incubator Thermo Fisher Scientific, Germering, Germany
HerasafeTMKS, biological safety cabinet Thermo Fisher Scientific, Germering, Germany
HLC HBT 130, thermo block Biometra, Goettingen, Germany
Leica TCS SP8 SMD Leica Microsystem, Wetzlar, Germany
Mikro 22R, centrifuge Hettich, Tuttlingen, Germany
NanoDrop 1000 Spectrophotometer Peqlab, Wilmington, USA
Stage top chamber Bold Line Okolab, Pozzuoli, Italy
SunriseTMMicroplate Absorbance Reader Tecan, Maennedorf, Austria
Vi-CellTMRX Cell Viability Analyzer Beckman Coulter, Fullerton, USA
VXR Vibrax R©, shaker IKA R©-Werke, Staufen, Germany
3.1.2 Consumables
Table 2
Product Supplier
Cell culture flasks, plates Sarstedt, Nuembrecht, Germany
Eppendorf Sace Lock Tubes Eppendorf, Hamburg, Germany
FACS tubes Sarstedt, Nuembrecht, Germany
Falcons TPP, Trasadingen, Switzerland
Haake W19, water bath Thermo Haake, Karlsruhe, Germany
IbidiTMµ-Slide 8 Well Ibidi, Munich, Germany
IbidiTMµ-Slide 12 Well, removable chamber Ibidi, Munich, Germany
Microscope glas slides and coverslips Fisher Scientific GmbH, Schwerte, Germany
Nitrocellulose membran, Hybond-ECLTM Amersham Bioscience, Freiburg, Germany
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3.1.3 Substances
Chondramide B and Chivosazole were kindly provided by Prof. Dr. Rolf Mu¨ller, Helmholtz
Centre for Infection Research, Saarland University, Saarbru¨cken, Germany. Jasplakinolide was
purchased from R&D Systems, Bio-Techne GmbH, Wiesbaden, Germany. Latrunculin B was
purchased from Sigma Aldrich, Taufkirchen, Germany. Miuraenamide A was kindly provided
by Prof. Dr. Uli Kazmaier, Institute for Organic Chemistry, Saarland University, Saarbru¨cken,
Germany. All actin binding substances were dissolved in DMSO and stored at -20◦C. Doxorubicin
hydrochloride was purchased from Sigma Aldrich, Taufkirchen, Germany, diluted in H2O and
stored at 4◦C.
3.1.4 Chemicals and reagents
All chemicals not listed in this section were purchased from Sigma Aldrich, Taufkirchen, Ger-
many.
Table 3
Product Supplier
2,2,2-trichloroethanol Sigma Aldrich, Taufkirchen, Germany
2,2’-azino-bis(3-ethylbenzothiazoline-6-sulfonic
acid)
Sigma Aldrich, Taufkirchen, Germany
7-AAD (7-Aminoactinomycin D) Fisher Scientific GmbH, Schwerte, Germany
Agarose, low gelling temperature Sigma Aldrich, Taufkirchen, Germany
Universal-Agarose, peqGOLD VWR Chemicals, Darmstadt, Germany
Amersham Hybond ECL nitrocellulose mem-
brane
GE Healthcare Europe, Freiburg, Germany
Amersham HybondP 0.45 PVDF membrane GE Healthcare Europe, Freiburg, Germany
Blotto (non-fat dry milk powder) Carl Roth, Karlsruhe, Germany
Bovine Serum Albumin Sigma Aldrich, Taufkirchen, Germany
Bradford reagent Roti R©-Quant Carl Roth, Karlsruhe, Germany
CellTiter-Blue R© Promega, Mannheim, Germany
CompleteTM (protease inhibitor) Roche diagnostics, Penzberg, Germany
Crystal violet Carl Roth, Karlsruhe, Germany
Dulbecco’s mofidifed Eagle’s medium PAN Biotech, Aidenbach, Germany
Dimethylsulfoxide Sigma Aldrich, Taufkirchen, Germany
Ethylenediaminetetraacetic acid Carl Roth, Karlsruhe, Germany
Fetal Calf Serum PAA Laboratories, Pasching, Austria
FluorsaveTM Reagent Millipore, Darmstadt, Germany
FuGENE R© HD Transfection Reagent Promega, Mannheim, Germany
GelRedTM Nucleic Acid Stain Biotium, Fermont, USA
Glutamine Sigma Aldrich, Taufkirchen, Germany
HiMarkTM Pre-Stained Standard Fisher Scientific GmbH, Schwerte, Germany
Hoechst 33342 Sigma Aldrich, Taufkirchen, Germany
Luminol AppliChem, Darmstadt, Germany
McCoy’s medium PAA Laboratories, Pasching, Austria
Na3VO4 Sigma Aldrich, Taufkirchen, Germany
Page Ruler Prestained Protein Ladder Germentas, St. Leon-Rot, Germany
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Table 3: continued from previous page
Product Supplier
Paraformaldehyde Polysciences, Pennsylvania, USA
Penicillin/Streptomycin 100x PAA Laboratories, Pasching, Austria
Phosphatase inhibitor Roche diagnostics, Penzberg, Germany
Protein A/G PLUS-Agarose (sc-2003) Santa Cruz Biotechnology, Inc., Heidelberg, Ger-
many
Puromycin hydrochloride Fisher Scientific GmbH, Schwerte, Germany
Pyronin Y AppliChem, Darmstadt, Germany
Pyruvate PAA Laboratories, Pasching, Austria
Rhodamine-phalloidin Life technologies, Darmstadt, Germany
Rotiphorese R© Gel 30 (37,5:1) Carl Roth, Karlsruhe, Germany
RPMI 1640 medium PAN Biotech, Aidenbach, Germany
Sodium dodecyl sulfate Carl Roth, Karlsruhe, Germany
Tris hydrochloride Sigma Aldrich, Taufkirchen, Germany
Triton X-100 Millipore, Darmstadt, Germany
Trypsin PAN Biotech, Aidenbach, Germany
Tween 20 VWR, Darmstadt, Germany
Yo-Pro R©-1 Iodide Fisher Scientific GmbH, Schwerte, Germany
3.1.5 Mixtures and kits
Table 4
Product Supplier
Duolink R© PLA Protein Detection Technology Sigma Aldrich, Taufkirchen, Germany
Liver Dissociation Kit, mouse (130-105-807) Miltenyi Biotec GmbH, Bergisch Gladbach, Ger-
many
3.1.6 General buffers and solutions
Buffers and solutions not mentioned here are specified in the respective method section.
PBS pH7.4 123.3mM NaCL, 10.4mM Na2HPO4, 3.2mM KH2PO4, H2O.
PBS+Ca2+/Mg2+ 136.9mM NaCl, 8.1mM Na2HPO4, 1.5mM KH2PO4, 2.7mM KCl, 0.5mM
MgCl2, 0.7mM CaCl2, H2O.
PBS-B 1mg/ml BSA, 0.01% sodium azide, PBS.
Trypsin/EDTA 0.05% Trypsin, 0.02% EDTA, PBS.
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3.1.7 Software
Table 5
Product Application Supplier
Adobe Reader PDF software Adobe Systems Software
Bibtex References Open source
FlowJo FACS analysis Tree Star Inc.
GraphPad Prism Data visualization, statistics GraphPad Software, Inc.
ImageJ Image analysis Open source
Inkscape Image editing Open source
JabRef References Open source
MagellanTM Protein concentration Tecan
Microsoft Office Package Data analysis, text editing Microsoft
Latex Text editing program Open-source
3.2 Methods
3.2.1 Cell culture
3.2.1.1 Cell lines
All cell lines used for this thesis are listed in (Tab. 6).
Table 6: Cell lines
Cell line Cell type Source
HeLa cervival cancer (human) DSMZ (Leibniz Institute, Braunschweig,
Germany)
T24 urinary bladder carcinoma (human) DSMZ (Leibniz Institute, Braunschweig,
Germany)
4T1-luc breast cancer (mouse) Perkin Elmer (Rodgau, Germany)
U2OS (I-SceI) bone osteosarcoma (human) [120]
HeLa and T24 cells were cultured in DMEM, 4T1 cells in RPMI. U2OS I-SceI reporter cell
lines were cultivated in McCoy’s medium + 1µg/ml puromycin.
3.2.1.2 Standard cell culture conditions
Cells were cultured under standard conditions (37◦C, 5% CO2, 95% humidity) in medium +
10% FCS + 1% Pen/Strep (complete medium, CM), depending on the cell line. All used cell
lines were cultured as adherent growing cells and had to be detached from the cell culture flask
by incubation with TE. Prior to any experiment, both cell density and viability were determined
with the ViCELL cell viability analyzer.
If not stated otherwise in all experiments for combination treatment of Doxo with any actin
substance, cells were pre-treated with each respective actin substance for 90mins before the
addition of Doxo. Maximum percentage of DMSO never exceeded 0.1%.
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3.2.1.3 Thawing and cryopreservation of cells
For cryoconservation, cell pellets (5min, 1500rpm) were suspended in 1ml FCS + 10% DMSO
and stored in liquid nitrogen. Cryopreserved cells were thawed at 37◦C for a few minutes and
then transferred to a tube with CM. After centrifugation (5min, 1500rpm), cell pellets were
resuspendend in fresh CM and transferred to a cell culture flask.
3.2.1.4 Transient transfection of cells
For transient protein overexpression, cells were plated 24h prior to the transfection. FuGENE R©
HD transfection reagent (Promega) was applied according to the manufacturer’s suggestion.
Follow-up experiments were conducted 24h after addition of FuGENE R© HD transfection reagent.
In case cells were treated with any substance, medium was changed to CM to exclude any possible
interference by the combination of reagents.
3.2.2 Cell viability and proliferation
3.2.2.1 Metabolic activity
Metabolic activity of HeLa and T24 cells was determined with the CellTiter-Blue assay (Promega)
adjusted from the manufacturer’s protocol. 5000 cells were seeded in 96-well plates in 100µl
medium and incubated for 24h, followed by treatment with Doxo [25nM] alone or in combi-
nation with actin substances LB [500nM] or Jaspla [50nM], respectively. After 72h, 20µl of
CellTiter-Blue reagent were added to each sample, incubated for 2-4h at 37◦C and fluorescence
signal measured at 530 nm with a microplate reader (SpectraFluor Plus, Tecan).
3.2.2.2 Colony formation assay
Clonogenic survival, after treatment with Doxo [250nM] and actin substances LB [1µM], Jas-
pla [100nM], was determined by colony formation assay. HeLa cells (1x105 cells/ well) or T24
(0.75x105 cells/ well) were seeded in 12-well plates and treated with Doxo alone or in combina-
tion with the respective actin substances for 2h. Cells were then washed with PBS, trypsinized,
counted and 1500 cells seeded in one well (6-well plate) in 3ml medium (performed in dupli-
cates). After 6 days, cells were washed with PBS, fixed in methanol (15 min) and cells stained
with crystal violet solution (30 min). Excess crystal violet was afterwards removed by washing
with H2O. Images of the individual wells were taken and total growth area was determined using
the ImageJ plugin ColonyArea.
Crystal violet solution 0.5% crystal violet, 20% methanol, H2O.
3.2.3 Flow cytometry
Cells used in this work usually emitted fluorescence after they had been infected with plasmids
that contained cassettes for GFP, or after staining with fluorophor-coupled secondary antibod-
ies. All experiments were either conducted with BD FACSCanto IITM (BD Biosciences) or
FACScalibur (BD Biosciences).
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As free Doxo shows fluorescence properties with an emission comparable to propidium iodide
(emission maximum at 560-590nm), alternatives had to be applied for flow cytometry analysis
of cell viability and cell cycle status of the cells (see 3.2.3.1 and 3.2.3.2. Doxorubicin fluorescence
is quenched, however after binding to DNA and thereby did not cause any problems for the
analysis of chromatin bound proteins (see 3.2.3.4).
3.2.3.1 YoPro exclusion assay
YoPro exclusion assay was performed to identify the proportion of apoptotic cells after treatment
with Doxo alone or in combination with actin substances. Cells were treated for 48h, harvested
in cold PBS-B and DNA stained with YoPro (YO-PROTM-1 Iodide (491/509), Thermo Fisher)
with a final YoPro concentration of 1µM and flow cytometry analysis was performed immediately
afterwards. In comparison to propidium iodide, not only dead but also apoptotic cells become
permeant to the dye.
3.2.3.2 Cell cycle analyses
To analyze the impact of combination therapy on cell cycle arrest, 7-AAD (ThermoFisher) was
applied, a fluorescent molecule and intercalating agent which binds like propidium iodide to
double stranded nucleic acids and can therefore be used to quantitatively assess DNA content
in cells by flow cytometry.
Cells were plated in 12 well plates ((1x105 cells/ well) and cultured in CM for 24h followed
by treatment with Doxo and the respective actin substances. After 48h cells were harvested,
spinned down (5min, 1500rpm), cell pellets washed with PBS and afterwards fixed with 250µM
methanol at 4◦C. Fixed cells were washed once more with PBS, resuspended in 250µl of PBS-B +
10µl/sample/7-AAD + 0.1mg/ ml RNAse A and incubated for 1h at 37◦C. First in a FSC/SSC
plot cell debris was excluded, then cell aggregates of two or more cells were removed and cell
cycle phases were analyzed in histograms with cell count erected over fluorescence intensity. The
percentage of cell death was calculated with a subG1 gate.
3.2.3.3 I-SceI-based reporter systems
Principle of the I-SceI-based reporter system. I-SceI-based reporter cell lines were used
to study DNA damage repair capacity after actin substance treatment (principle presented in
[120]). These reporter cell lines express GFP-expression cassettes that are interrupted by one or
more recognition sites for the endonuclease I-SceI. Transient overexpression of I-SceI (pCBAS-
ceI, addgene plasmid nr.26477, [121]) leads to one or more cuts in the GFP cassette, and upon
repair via the respective DNA repair pathway, the cell restores the correct GFP sequence, which
can be measured by flow cytometry (percentage of GFP+ cells). In this work, four reporter cell
lines were used (see Tab. 7 and Fig. 7). In the DR-GFP cell line, the GFP cassette harbors one
I-SceI recognition site and a 5’ and 3’ truncated iGFP that serves as a repair template which
is required for homology directed repair (HDR). The construct used for the SA-GFP cell line
harbors two GFP fragments (a 5’ and a 3’ truncated fragment), which share 266nt homology
and are separated by 2.7kb. Here, the I-SceI recognition site is localized in the 3’ fragment and
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successful single strand annealing will lead to a GFP+ product. The GFP expression cassette of
the EJ2 cell line is separated from the promoter by the I-SceI recognition site which is followed
by a sequence of several stop codons. The I-SceI site and the stop codon sequence are surrounded
up- and downstream by an 8nt microhomology. Alternative end joining (alt-EJ) will lead to a
deletion of the stop codons (35nt) and the restoration of a functional GFP. The cell line EJ5-
GFP contains a GFP cassette that harbors two I-SceI recognition sites and is separated from the
promotor by a puromycin resistance marker. Distal non-homologous end joining (NHEJ) leads
to a deletion of the puromycin sequence and thereby restores the expression of a functional GFP.
Table 7: U2OS I-sceI-based reporter cell lines
Cell line DNA DSB repair pathway
DR-GFP Homology directed repair (HDR)
SA-GFP Single strand annealing (SSA)
EJ2-GFP Alternative end joining (alt-EJ)
EJ5-GFP Non-homologous end joining (NHEJ)
Figure 7: Principle of the I-SceI-based reporter system. A DR-GFP. The GFP cassette is interrupted
by an I-SceI recognition site and 5’ and 3’ truncated iGFP can serve as a template during HDR. B SA-
GFP. The construct harbors two GFP fragments (a 5’ and a 3’ truncated fragment) that are oriented
in the same direction, share 266nt homology and are separated by 2.7kb. The 3’ fragment harbors
the I-SceI recognition site. C EJ2-GFP. The GFP is connected upstream to a tag and separated
from it by the I-SceI recognition site and a sequence of several stop codons. Both are surrounded by
an 8nt microhomology. Alt-EJ will lead to a deletion of the stop codons (35nt) and a GFP-positive
product. D EJ5-GFP. The GFP cassette harbors two I-SceI recognition sites and is separated from
the promotor by a puromycin resistance marker (puro). Distal NHEJ will delete the puro sequence
and restore the expression of GFP.
Experimental setup. U2OS-I-SceI reporter cells were seeded (1x105cells/ well) and trans-
fected on the fowolling day in duplicates with the above mentioned pCBASceI plasmid to tran-
siently overexpress the I-SceI endonuclease. After 6h of incubation, medium was changed to
normal CM and actin substances added, LB [500nM], Jaspla [50nM], ChB [75nM]. In case of
the EJ5 cell line, medium without puromycin had to be applied, as successful repair deletes the
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puromycin resistance. After 72h, cells were harvested in PBS-B and flow cytometry performed
with viable cells. Cell debris and dead cells were excluded with a linear SSC-A/ FSC-A gate,
cell doublets eliminated with a linear FCS-W/ FSC-A gate and the percentage of GFP+ cells
measured.
3.2.3.4 Chromatin association of DNA damage repair proteins
Recruitment of DNA damage repair factors to the site of damage can be measured by flow
cytometry if the respective protein is directly or indirectly bound to chromatin after induction
of DNA damage. This allows the analysis of larger cell populations compared to the standard
foci formation immunocytochemistry protocol. The functionality of this approach was published
in [122] and the assay performed accordingly. HeLa cells were seeded in 12 well plates ((1x105
cells/ well) 24h prior to the experiment. The next day, cells were treated with Doxo [250nm]
for 2h alone or in combination with the respective actin substance and afterwards harvested in
cold PBS. In the next crucial step, cells were resuspended in extraction buffer and incubated on
ice for 5-10mins to extract unbound protein. Cells were then washed in PBS-B and fixed with
4% PFA in PBS for 15mins at room temperature and washed with cell washing buffer once.
Primary antibodies (Tab. 8) were diluted in cell washing buffer and cells incubated for 1h at
room temperature or at 4◦C over night, washed once with cell washing buffer and incubated for
30mins at room temperature with the respective secondary antibody (Tab. 9), washed again and
resuspended in PBS-B for FACS analysis. Prior to the actual FACS analysis, compensation was
performed as 2 colors were measured with one laser (RPA-2: PE, yH2AX: 488). Compensation
beads for unstained, PE and FITC channels were used (antibodies see Tab. 9) and compensation
performed according to the manufacturer’s (BD Biosciences) protocol. Cell debris was excluded
with a linear SSC-A/ FSC-A gate, single cells isolated using a linear FCS-W/ FSC-A gate and
positive cells defined by a third gate in a log 488/ PE histogram. In this work, chromatin asso-
ciation of RPA-2 and yH2AX upon DNA damage induction was analyzed.
Extraction buffer 0.2% Triton X-100, PBS.
PBS-B 1mg/ml BSA, PBS.
Washing buffer 1% FCS, 0.1% sodium acide, 0.1% saponine, PBS.
Table 8: Primary antibodies for chromatin association assay
Protein Provider Species Dilution
Histone H2A.X phospho-Ser-130 (yH2AX) Cell Signaling (2577) Rabbit 1:200
RPA-2 Abcam (ab2175) Mouse 1:500
Table 9: Secondary antibodies for chromatin association assay
Fluorophore Provider Species Dilution
Alexa Fluor 488 Thermo Fisher (A11034) Goat anti-rabbit 1:1000
PE BD Biosciences (550083) Rat Anti-mouse IgG1 1:1000
FITC isotype control BD Biosciences (557721) Mouse 20µl/sample
PE k isotype control BD Biosciences (556029) Mouse 20µl/sample
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3.2.4 Microscopy
3.2.4.1 Alkaline comet assay
Cells were seeded 24h prior to the experiment in 12-well plates. After treatment of cells with
Doxo [250nM] and the indicated actin substances for 2 hours, Doxo was removed and medium
replaced with or without the respective actin substances for 4 hours (repair time). Doxo treat-
ment without any repair time served as positive control. Approximately 1x104 cells were then
seeded in agarose (0.7% in PBS, low gelling) at 37◦C on pre-coated glas slides (0.8% in PBS,
pre-coating performed twice), incubated on ice for 10mins and lysed at 4◦C over night in comet
lysis buffer. After lysis, electrophoresis was performed at 4◦C at 35 V for 15 min with a current
flow of approximately 250mA. After electrophoresis, glass slides were incubated in neutraliza-
tion buffer for 10min, and then stained with 1x GelRedTM (Thermo Fisher Scientific) in H2O
for 15min, followed by three washing steps in H2O and fixation in 70% ethanol. Glass slides
were sealed with FluorSaveTM (EMD Millipore) and images taken with a 20x or 40x objective.
Images were analyzed with OpenComet (ImageJ) and tail moments calculated and normalized
on Doxo repair samples or untreated controls.
Comet lysis buffer 0.1M EDTA-Na2, 2.5M NaCl, 10mM Tris HCl, 1% Triton-X 100, NaOH
(ad. pH=10), H2O.
Comet electrophoresis buffer 1.5M NaCl, 5mM EDTA-Na2, 0.5M NaOH, H2O.
Comet neutralization buffer 0.4M Tris HCl, NaOH (ad. pH=7), H2O.
3.2.4.2 General immunocytochemistry protocol
Between 1x and 2x104 cells per well were seeded and cultivated for at least 24h before starting
any treatment. Cells were then washed with cold PBS, and fixed with 4% PFA for 15mins at
room temperature, permeabilized with 0.2% Triton-X 100 for 10mins, blocked with 5% BSA in
PBS for at least 30mins at room temperature and stained with the primary antibody over night
at 4◦C. The next day, cells were washed once with PBS, then incubated for at least 30mins
in the secondary antibody, washed again and co-stained for actin and nuclei with rhodamine
phalloidin (Thermo Fisher Scientific) and Hoechst (Thermo Fisher Scientific), respectively. Cells
were then mounted with one drop of FluorSaveTM (EMD Millipore). Images were taken with a
Leica SP8 microscope featuring a 63x objective and analyzed with ImageJ.
Table 10: Antibodies and dyes for immunocytochemistry
Type Target Provider Species Dilution
Primary yH2AX Cell Signaling (2577) Rabbit 1:500
Primary RPA-2 Abcam (ab2075) Mouse 1:250
Primary DNA-PK (T2609) Abcam (ab18356) Mouse 1:150
Secondary anti-mouse Invitrogen (A11001) Goat 1:500
Secondary anti-rabbit Invitrogen (A11008) Goat 1:500
Rhodamine/phalloidin actin Thermo Fisher Scientific - 1:400
Hoechst 33342 DNA Thermo Fisher Scientific - 1:50
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3.2.4.3 Chromatin texture
Cells were seeded in ibidi 8 well µ-slides and treated wih the respective substances. Cells were
then fixed in 4% PFA for 10min, permeabilized in 0.05% Trion X-100 for 5min, washed twice with
PBS and stained with Hoechst (2µg/ml) for 15min and mounted with FluorsaveTM. Images were
taken with a Leica TCS SP8 with a resolution of 4096x4096, image acquisition speed at 400hz
and 6 line averages. Hypotonic treatment (media 35:65 water) and hypertonic treatment (320
mM sucrose in media) were applied for 10min before fixing of the cells as controls for chromatin
relaxation or condensation respectively. Images were analyzed with the GLCM Texture plugin
(ImageJ).
3.2.4.4 Chromatin relaxation assay
U2OS pa-GFP H2B expressing cells were plated the day before the experiment. Prior to imaging,
cells were pre-treated for 90 minutes with the indicated actin substances, followed by Hoechst
treatment for 1h alone or in combination with the respective actin substance. DMSO treated
cells served as control. Specific nuclear areas were photoactivated by the 405 nm laser to induce
local DNA damage and followed up over time (36 cells each sample). For decondensation as-
say, chromatin relaxation was measured every 4 seconds for 120s. To evaluate recondensation,
chromatin relaxation was measured for 990s after induction of DNA damage (mean value of 36
cells).
3.2.4.5 Nuclear run-on assay
Cells were treated with the indicated substances and 5mM 5-Fluorouracil (5-FU) (Sigma Aldrich)
was added for the last 70min. Fixation and staining was performed as described in 3.2.4.2.
Cells were stained with anti-BrdU antibody (B8434, Sigma Aldrich) as primary antibody and
Alexa Fluor 488 (A11001, Invitrogen) as secondary antibody. Percentages of positive cells were
calculated. Treatment with actinomycin D (7.5µg/ml, Sigma Aldrich) served as positive control
for transcriptional inhibition.
3.2.4.6 Foci formation assay
1.5x104 cells per well were seeded in 8-well slides (Ibidi) and treated with Doxo [250nM] for 2h,
with or without repair time, and in combination with different actin substances as indicated.
Fixation and staining was performed as described in 3.2.4.2. The number of foci was either
counted manually or with the FindFociGUI (ImageJ) plugin.
3.2.4.7 Duolink assay
To show a possible binding of actin to nuclear DNA damage repair factors on a single cell basis,
a proximity ligation assay - Duolink R© assay - was performed according to the providers’ sugges-
tions (Sigma Aldrich). Briefly, cells were seeded in 12-well (removable) microscopy slides (Ibidi)
and treated the next day with Doxo [250nM] for 1h in combination with the actin substances
or transfected with actin plasmids YFP NLS Beta-Actin (control plasmid, addgene plasmid
60613), YFP NLS Beta-Actin G13R (depolymerization mutant, addgene plasmid 60615), YFP
32
3 Materials and Methods
NLS Beta-Actin S14C (polymerization mutant, addgene plasmid 60614) 24h prior to the exper-
iment. Cells were then fixed with 4% PFA for 15mins at room temperature, permeabilized with
0.2% Triton X-100 for 5min and blocked with 1% BSA in PBS for 20mins. Primary antibodies
were added to the cells (see Tab. 11) and incubated for 1h at room temperature and, after one
washing step, Duolink R© assay was performed. For Doxo treated samples, Duolink R© In Situ De-
tection Reagents Green were used, while for YFP transfected cells Duolink R© In Situ Detection
Reagents Red. Images were taken with the Leica SP8 microscope and analyzed with ImageJ.
Numbers of positive events in nuclei were counted manually.
Table 11: Duolink R© antibodies
Target Provider Species Dilution
RPA-2 Abcam (ab2075) Mouse 1:250
DNA-PKcs Cell Signaling (12311) Mouse 1:50
Actin Sigma Aldrich (A2066) Rabbit 1:100
Ku70 Abcam (ab92450) Rabbit 1:200
Actin Sigma Aldrich (AMAB91241) Mouse 1:200
3.2.4.8 Life cell imaging
For life cell imaging of transfected cells a stage top cell chamber (Bold Line, Okolab) was installed
on a Leica SP8 microscope to maintain the required culturing conditions (37◦C, 5% CO2, 95%
humidity). To visualize actin in living cells, different plasmids were used (see Tab. 12).
Table 12: Actin plasmids for life cell imaging
Plasmid Source
Actin-GFP addgene (plasmid 21948)
Actin-mCherry addgene (plasmid 54966)
Actin-Chromobody R© (GFP) ChromoTek GmbH, Planegg-Martinsried,
Germany
3.2.4.9 Fluorescence correlation spectroscopy
FCS measurements were performed on a Leica TCS SP8 SMD microscope together with the
Picoquant LSM Upgrade Kit. Cells were seeded in ibidi 8 well µ-slides with glass bottoms and
transfected with Actin-GFP (addgene plasmid 21948) 24h prior to the FCS measurement. The
effective volume (Veff) and structure parameter (κ) were measured prior to each independent
experiment (see equation below) using 1nM ATTO488 dye solution (ATTO-TEC GmbH, Siegen,
Germany). In every selected nucleus (five nuclei each round), three different points were mea-
sured for 45s per point at 4 different time points (0, 10, 30, 60min). Doxorubicin [250nM] was
added after the zero-time point measurement. Control measurements without the addition of
any compound were performed accordingly to verify that photobleaching does not influence the
analysis. FCS curves were analyzed with the Picoquant SymPhoTime V 5.2.4.0 software and
fitted with a single diffusing species and a triplet state.
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3.2.5 Protein Biochemistry
3.2.5.1 Lysis of cells
Cells were harvested and washed with cold PBS and lysed with cell lysis buffer (dependent on
the experiment) + protease inhibitor (1:25) + phosphatase inhibitor (1:10). Cell lysates were
cleared by centrifugation (10min, 10000rpm, 4◦C) and protein lysates stored at -20◦C.
For determination of protein concentrations, the BCATM Protein Assay Kit (Thermo Sci-
entific) was used and the absorption of each sample measured with an ELISA reader (Tecan,
Magellan).
3.2.5.2 Western blot
For standard western blot assay, cells were lysed with Milanese buffer. For separation of proteins
SDS polyacrylamide electrophoresis was performed using polyacrylamide gels (8-12%; 10-well
and 15-well) and sodium dodecyle sulfat (SDS) buffers. For denaturation 5x sample buffer was
added to the protein sample to a final concentration of 1x and boiled for 5min at 95◦C. Samples
were then loaded unto polyacrylamide gels and electrophoresis was performed (20min at 200V
followed by 45min at 100V). After electrophoresis proteins were transferred to nitrocellulosis
or PVDF membranes by tank blotting at 100V for 100min or at 30V overnight depending on
the size of the protein of interest at 4◦C. Non-specific binding was blocked by incubation in
blocking solution for 1h at room temperature and was then washed with TBS-T three times
for 10min. The membrane was afterwards incubated in the primary antibody (in blocking so-
lution) at 4◦C overnight. The next day the membrane was washed with TBS-T three times for
10min and then incubated with a suitable secondary HRP-conjugated antibody for 1h at room
temperature. The membranes were incubated with HRP Homemade ECL solution and analyzed
by ChemiDoc Touch Imaging System (Bio-Rad). The band intensities of detected proteins were
calculated by ImageLab (Bio-Rad) and normalized to the total protein amount (stainfree gel)
or actin or tubulin as loading control.
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Table 13: Antibodies for western blot
Target Provider Species Dilution
RPA-2 Abcam (ab2075) Mouse 1:1000
DNA-PK Cell Signaling (12311) Mouse 1:1000
Actin Sigma Aldrich (A2066) Rabbit 1:1000
Actin MAB1501 (Millipore) Mouse 1:1000
Ku70 Abcam (ab92450) Rabbit 1:1000
yH2AX Ser139 Cell Signaling (2577S) Rabbit 1:1000
p-Chk2 Thr68 Cell Signaling (2661) Rabbit 1:1000
p-ATM Ser1918 Cell Signaling (5883) Rabbit 1:1000
anti-mouse (HRP) abcam (ab97240) Goat 1:10000
anti-rabbit (HRP) Dianova (111-035-144) Goat 1:10000
Milanese lysis buffer 50mM Tris, HCl (pH8), 150mM NaCl, 1% NP40 0.5% sodium deoxy-
cholate, 0.1% SDS, 300µM Na2VO3, 1mM NaF, 3mM ß-glyerophosphate, 10mM pyrophosphate,
H2O. Freshly added prior to experiment: 20mM H2O2, 200mM PMSF, protease inhibitor cocktail
(Roche), phosphatase inhibitor cocktail (Roche).
5x sample buffer 3.13M Tris HCl (pH 6.8), 10% Glycerol , 20% SDS , 16% DTT, 5% Pyronin
Y, H2O. 1x SDS sample buffer diluted 1:5 in H2O.
Separating gel 5ml 30% Rotiphorese R©, 3.75ml 1.5M Tris HCl (pH8.8), 150µl SDS 10%, 6.1ml
H2O, 0.5% 2,2,2-trichloroethanol, 15µl TEMED, 75µl 10% APS.
Stacking gel 1.275ml 30% Rotiphorese R©, 750µl 1.25M Tris HCl (pH6.8), 75µl 10% SDS, 5.25ml
H2O, 15µl TEMED, 75µl 10% APS.
5x Electrophoresis buffer 24.8mM Tris-base, 191.8mM Glycine, 3.5mM SDS, H2O. For 1x
buffer diluted in H2O.
5x Tank buffer 25mM Tris-base, 192mM Glycine, H2O. For 1x buffer diluted in H2O + 20%
methanol.
TBS-T (pH8.0) 24.8mM Tris HCl, 190mM NaCl, 0.2% Tween 20, H2O.
Blocking solution PBS + 0.02% Tween20 + 5% non-fat dry milk/BSA.
HRP Homemade ECL 1.25mM Luminol, 0.2mM Cumaric acid, 0.1M Tris-base HCl (pH8.5),
0.009% H2O2, H2O.
3.2.5.3 Co-immunoprecipitation
Cells were lysed with hypotonic buffer, cell suspension passed thrice through a syringe (25G
needle) and nuclei isolated by centrifugation (10000rpm, 10min, 4◦C). Nuclei were lysed with
nuclei lysis buffer, suspension passed twice through a 30G needle, two sonification pulses were
applied and suspension spinned down (10000rpm, 10min, 4◦C). Cell residues were discarded.
20µl of the resulting protein sample were used for immunoblotting as an input control. The
rest was incubated with 10µl of the respective pulldown antibody for 2h at 4◦C (see Tab. 14).
Protein samples of untreated cells incubated only with beads, or with beads + the respective
IgG Control were used as negative controls. Agarose beads (Protein A/G PLUS-Agarose, Santa
Cruz) were then added for one more hour followed by washing of beads twice with nuclei lysis
buffer and twice with PBS + 150mM KCl + 2mM MgCl2. Immunoprecipitates were collected by
centrifugation at 2500rpm for 5min at 4◦C. After the last washing step, beads were resuspended
in 40µl 1x sample buffer and boiled at 95◦C for 5min and immunoblotting performed for both
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pulldown protein and the respective potential binding partner (as described in 3.2.5.2).
Hypotonic buffer 10mM HEPES (pH7.9), 1.5mM MgCl2, 10mM KCL, 0.5mM DTT, 0.1%
NP-40 (v/v), ad. H2O.
Nuclei lysis buffer 20mM HEPES (pH7.9), 20% glycerol, 2mM MgCl2, 150mM KCL, 0.2mM
EDTA, 0.5mM PMFS, 0.5mM DTT, ad. H2O.
Table 14: Antibodies for Co-immunoprecipitation
Target Provider Species
RPA-2 Abcam (ab2075) Mouse
Actin Sigma Aldrich (A2066) Rabbit
Ku70 Abcam (ab92450) Rabbit
Normal rabbit IgG (Control) Cell Signaling (2729) Rabbit
Normal mouse IgG (Control) Santa Cruz (sc2025) Mouse
3.2.6 In vivo tumor mouse model
BALB/cOlaHsd female mice were obtained from Envigo (Netherlands) at an age of 6 weeks and
experiments started at the age of 8 weeks. All performed animal experiments were approved by
the District Government of Upper Bavaria in accordance with the German Animal Welfare and
Institutional guidelines.
A tumor mouse experiment was performed to show DNA damage repair inhibition in vivo
(Fig. 8). 1x106 4T1-luc cells per mouse were diluted in 100µl PBS and injected subcutaneously.
Tumors were grown for 7 to 10 days before the start of treatment. Mice were treated with 3mg/kg
Doxorubicin i.v. (diluted in PBS) alone or in combination with 0.1mg/kg Latrunculin B, i.p.
(5% DMSO + 10% solutol in PBS) for 24h. Mice were then sacrificed and tumors harvested,
mechanically disrupted and incubated in enzyme mix (Miltenyi Biotech) for 45min at 37◦C.
Digested tissue was then filtered through cell strainers with a size of 40µm to obtain single cell
suspensions. Cells were counted and seeded accordingly for alkaline comet assay (performed as
described in 3.2.4.1).
Figure 8: Setup of xenograft mouse model.
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3.2.7 Statistics
Unless stated otherwise, all experiments were performed three times in independent experiments.
Dependent on the assay, one-way ANOVA test with relevant post tests (Dunnetts Multiple Com-
parisons or Sidaks multiple comparisons test) or t-test (paired or unpaired) were used to assess
the significance of difference between treatment groups as indicated in each respective experi-
ment. P-values <0.05 were considered significant.
Potential synergism of combination treatment was assessed by calculation of Bliss value with
normalized values (NV). All bliss values >1 were considered synergistic.
The statistical analysis was conducted with GraphPad Prism 7.
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4.1 Actin and its role in nuclear DNA damage repair processes
Actin reorganization has been suggested to be induced during DNA damage response (DDR),
although its direct role in nuclear DNA damage repair signalling processes has not been inves-
tigated yet to a greater extent. Nuclear actin has been described to be polymerized upon DNA
damage induction and is therefore assumed to be required for the functioning of DNA repair
[79]. However, only very few studies have been published so far that show a direct link of actin
to DNA damage repair factors. There is hence still the need for further investigations to obtain
a better understanding of nuclear actin regulation during DNA damage repair signalling and to
answer the question whether nuclear actin is indeed involved in DNA DSB repair and if yes, how.
To study DNA damage response, DNA DSBs were introduced by doxorubicin treatment. Actin
manipulation was achieved by either overexpression of actin mutant plasmids or treatment with
actin binding compounds. Low doses of actin binders were applied to analyze specific effects of
actin manipulation on DNA damage responses and to avoid unwanted cytotoxic effects. Mostly,
classical actin binding substances, namely latrunculin B (actin depolymerizer) and jasplakinolide
(actin polymerizer) were applied.
4.1.1 Actin binders influence cytoplasmic and nuclear actin.
Effects of low dose treatment with actin binders on actin morphology, both in the cytoplasm
and in the nucleus, were examined.
In the cytoplasm, low dose treatment with the actin depolymerizer LB resulted in a fast
disruption of the actin cytoskeleton structure after only 30 minutes, which led to shrinkage of
cells and loss of cell-cell contacts. Those strong morphological changes were found to remain
stable for at least three hours. Cytoplasmic actin filaments started to form again six hours after
application of LB and after 24 hours, the structure of the actin cytoskeleton in the cytoplasm
was completely recovered (Fig. 9).
Treatment with the polymerizer Jaspla caused formation of actin aggregates in the cytoplasm
that started to be visible 90 minutes after substance application and were stable for up to 24
hours. Cell-cell contacts were not completely lost by Jaspla treatment (Fig. 9).
HeLa cells transfected with an actin-GFP plasmid revealed differential changes in nuclear actin
levels upon application of actin binders. LB treatment resulted in elevated nuclear fluorescence
signals, i.e. in a rather fast accumulation of actin in the nucleus (Fig. 10A). On the contrary,
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Figure 9: Effects of actin binders on cytoplasmic actin. HeLa cells were treated with latrunculin B [500nm]
or jasplakinolide [100nM]. Cells were fixed at the indicated time points, permeabilized and stained
for F-actin (rhodamine-phalloidin, red) and DNA (Hoechst, blue). White arrows mark jasplakinolide
induced actin aggregates.
Jaspla slightly diminished nuclear actin levels (Fig. 10A). Independent of the character of actin
manipulation, an increased polymerization of nuclear actin was triggered upon overexpression of
the nuclear actin-Chromobody R© plasmid (ChromoTek) in combination with either LB or Jaspla
treatment (Fig. 10B).
Thus, in addition to the obvious effects of actin binders on cytoskeletal actin, influences on
nuclear actin were detected as well. Interestingly, changes in protein levels of nuclear actin were
found to be dependent on the class of the actin binding compound, whereas alterations in the
polymerization state of nuclear actin were not.
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Figure 10: Effects of actin binders on nuclear actin. A Nuclear actin levels. HeLa cells were transfected
with actin-GFP and life cell imaging was performed. Fluorescence intensities in the nucleus were
measured at the indicated time points after addition of the actin binding substances. Mean values
of two ROIs each of at least 15 cells (three independent rounds) are depicted. B Nuclear actin
polymerization. HeLa cells were transfected with nuclear actin-ChromobodyR© plasmid, treated
with the indicated actin substances for 2h, then fixed, permeabilized and stained with rhodamine-
phalloidin and Hoechst. The number of cells positive for nuclear actin aggregates was counted.
Exemplary nuclear actin filaments are highlighted by white arrows. Mean values of at least three
independent experiments (+/- SEM) with at least 20 cells per experiment are shown.
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4.1.2 Manipulation of the actin equilibrium inhibits DNA double strand break
repair.
Single cell electrophoresis (comet assay) was performed in order to analyze whether actin is
involved in the repair of Doxo induced DSBs. Actin was manipulated either by treatment of
cells with actin binders (Fig. 11A) or by overexpression of mutant actin plasmids (Fig. 11B).
The repair of double strand breaks induced by Doxo treatment was inhibited independently of
the type of actin manipulation (Fig. 11). Both a decrease of polymerized actin due to actin de-
polymerizers (LB or chivosazole A) or transfection with G13R-NLS-YFP (actin polymerization
mutant) and the increase of polymerized actin by treatment with actin polymerizers (Jaspla,
ChB or miuraenamide A) or over expression of S14C-NLS-YFP (actin depolymerization mu-
tant) led to impaired DNA damage repair. Pre-treatment with actin binding substances prior to
addition of Doxo achieved stronger effects on the repair capacity. On the contrary, no increased
DNA damage was detected with actin manipulation alone. Elevated levels of DSBs are therefore
unlikely to derive from accumulation of DNA damage, but are rather caused by defects in DNA
damage repair due to additional actin manipulation.
Thus, a tight control of the actin equilibrium in the cytoplasm and/or the nucleus seems to
be required for functional repair of Doxo induced DNA DSBs.
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Figure 11: Actin manipulation inhibits DNA damage repair. A Actin binding compounds. HeLa
cells were treated with 250nM Doxo for 2h with or without addition of the indicated actin sub-
stances (pre = pretreatment with actin substance for 90mins). Doxo was then removed and cells
incubated in DMEM (Doxo Repair) or DMEM + the respective actin substance. Doxo treatment
alone without repair time served as positive control. Images were analyzed with OpenComet (ImageJ,
output examples shown on the left) and tail moments calculated. Relative tail moments are shown
(normalized on Doxo repair samples). Comet assays with chivosazol A and miurenamide A performed
by Anja Arner. B Actin mutants. Cells were transfected with G13R-NLS-YFP or S14C-NLS-YFP,
24h prior to the induction of DNA damage with Doxo and comet assay performed as described in A.
Untransfected cells were used as a negative control.
Mean values (+/- SEM) of at least three independent experiments are shown (one-way ANOVA,
*p<0.05, **p<0.01, ***p<0.005,****p<0.0001, ns not significant).
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4.1.3 Doxorubicin induced DNA damage affects nuclear actin states.
The formation of nuclear actin filaments upon DNA damage induction has been suggested to be
required for DNA damage repair [79, 113]. Nevertheless, the influence of DNA DSB signalling
on nuclear actin organization and vice versa is still not well understood.
Actin polymerization upon DNA damage induction in HeLa cells transfected with the nuclear
actin probe nuclear actin-Chromobody R© could be confirmed. The number of cells with nuclear
GFP-positive actin aggregates was strongly increased upon Doxo treatment (Fig. 12A). Addi-
tional co-transfection experiments were performed to exclude the possibility that the observed
effect is only caused by a shift of actin to the nucleus due to the overexpression of an actin bind-
ing antibody that is fused to a NLS (i.e. the nuclear actin-Chromobody R©). Co-transfection of
mCherry-actin (without a NLS) and the nuclear actin-Chromobody R© did not lead to increased
mCherry-actin levels in the nucleus (Fig. 12B). In order to analyze if DNA damage leads to nu-
clear import or export of actin, cells were transfected with actin-GFP, and fluorescence intensity
ratios of nucleus to cytoplasm measured before and 1h after addition of Doxo. No significant
changes in the ratio of actin levels could be observed (Fig. 12C), which implies that actin reor-
ganization in the nucleus is not caused by import from or export to the cytoplasm. With this
experimental setup, no nuclear actin aggregates could be observed. Although chromobody over-
expression did not significantly alter nuclear actin levels, it cannot be excluded that it artificially
stabilizes established actin structures, leading to disproportionate effects (reviewed in [123]). To
circumvent this problem and strengthen the finding that actin is reorganized in the nucleus upon
DSB induction, FCS measurements were performed (Fig. 12D). Upon DNA damage induction
by Doxo treatment, concentrations of free nuclear actin (actin-GFP) were significantly decreased
in a time dependent manner (Fig. 12D2), whereas diffusion coefficients remained at a similar
value (Fig. 12D3). A decrease of free actin in the nucleus could be explained by an export of
actin to the cytoplasm (which was not observed in (Fig. 12C)) or by an increase in the immobile
(not measurable) actin fraction due to actin polymerization or recruitment.
Hence, induction of DSBs indeed seems to alter the state of actin in the nucleus shifting the
equilibrium to a more polymerized/immobile actin fraction. This observation rises the ques-
tion which role the recruitment and/or polymerization of actin plays in DNA damage induced
signalling.
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Figure 12: Influences of Doxo induced DNA damage on nuclear actin. A Nuclear actin polymeriza-
tion. After transfection with ChromobodyR©, HeLa cells were treated with Doxo and cells positive for
nuclear actin aggregation counted. Mean values (+/- SEM) are shown (unpaired t test, two-tailed,
***p<0.005). B Influence of nuclear actin-ChromobodyR© on nuclear actin level. Cells were
transfected with mCherry-actin alone or in combination with ChromobodyR© and fluorescence inten-
sity of nuclear mCherry expression was measured. Single values of three independent experiments
are depicted (unpaired t test, two-tailed, ns not significant). C Nuclear actin level. Cells over-
expressing actin-GFP were treated with Doxo, and fluorescence intensities measured before and 1h
after addition of Doxo (mean values of two ROI per cell). Graph shows ratio of measured intensities
of nucleus to cytoplasm. Up to 20 cells in three independent rounds were analyzed. D FCS. Cells
overexpressing actin-GFP were treated with Doxo and single points FCS measurement of nuclear
actin was performed at the indicated time points. D1. Example pictures of one round are shown and
corresponding fitting curves of one cell (indicated by purple rectangle) depicted. Nuclear concentra-
tions of actin D2 and diffusion coefficients D3 were determined in three independent experiments
(at least 30 cells). Untreated cells served as control (10 cells). Graphs show mean values +/- SEM.
**** p<0.0001, paired t test, two-tailed. Analysis of FCS measurement performed by Themistoklis
Zisis.
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4.1.4 Actin binding substances do not affect chromatin structure and overall
transcriptional activity at low concentrations.
Chromatin reorganization plays a role in DSB repair, it is e.g. important for repair factor re-
cruitment. The nuclear matrix is mainly composed of actin [88]. The local reorganization of
the chromatin structure might therefore depend on the state of actin. As a consequence, actin
manipulation could alter DSB induced chromatin changes, resulting in impeded DNA damage
repair.
Doxorubicin has been described to induce chromatin compaction (measured in isolated chro-
matin) [124], although the role of this process has not been specified yet. Global condensation
and relaxation can be measured by analysis of chromatin texture upon staining of DNA with
Hoechst in fixed cells. An increase in contrast and a decrease of correlation compared to the
control indicates chromatin compaction (e.g. after hypertonic treatment), whereas the decrease
in contrast and increase of correlation indicates relaxation (hypotonic treatment). Single treat-
ment with LB and Jaspla did not lead to changes in global chromatin texture (Fig. 13). The
minor global chromatin compaction upon Doxo treatment was not impaired in combination with
Jaspla and only slightly altered in combination with LB (Fig. 13).
Figure 13: Low dose treatment with actin binders does not change global chromatin texture. After
treatment, cells were fixed and permeabilized and stained for Hoechst. Hypotonic treatment (media
35:65 water) and hypertonic treatment (320mM sucrose in media) were applied as positive controls
for chromatin relaxation or condensation, respectively. Images were taken with a Leica TCS SP8
with a resolution of 4096x4096 and analyzed with the GLCM Texture plugin (ImageJ).
Local chromatin relaxation occurs upon DSB formation and is required for efficient DNA re-
pair as only relaxed chromatin allows recruitment of specific DNA damage repair proteins to the
site of damage [125, 126]. To analyze whether changes in chromatin structure by administration
of actin binding substances impairs local DNA damage mediated chromatin decondensation,
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chromatin relaxation was measured with or without precedent actin binder treatment in U2OS
pa-GFP H2B expressing cells (Fig. 14). None of the applied actin binders impeded chromatin
decondensation during the first 120 seconds after local UV-induced DNA damage (Fig. 14A).
Following the DSB induced relaxation, chromatin structures are usually quickly re-established
[126]. Chromatin recondensation was still functioning in the presence of Jaspla and was not
delayed (Fig. 14B).
Figure 14: Chromatin relaxation upon DNA damage induction. U2OS pa-GFP H2B expressing cells
were plated the day before. Prior to imaging, cells were pre-treated for 90 minutes with the indicated
actin substances, followed by Hoechst treatment for 1h alone or in combination with the respective
actin substance. Specific nuclear areas were photoactivated by the 405 nm laser to induce local DNA
damage and followed up over time. A Decondensation. Cells were treated with the indicated
actin substances (LB [1M], Chivo [7nM], Jaspla [100nM], ChB [75nM], Miu [25nM]) and chromatin
decondensation was measured every 4 seconds for 120s (36 cells each sample, n=2-3). DMSO treated
cells served as control (one exemplary image of control cells 0min and 2min after induction of damage
is shown on the left). B Recondensation. Chromatin relaxation of Jaspla treated cells was measured
for 990s after induction of DNA damage (mean value of 36 cells). DMSO treated cells served as
control.
Chromatin relaxation assays performed by Rebecca Smith at the department of Physiological Chem-
istry, LMU, Munich.
Global chromatin compaction by Doxo treatment and local chromatin relaxation upon UV-
induced damage was not impeded by the addition of actin binders at low concentrations. In-
hibition of DNA damage repair is thus most likely not caused by general obstruction of repair
factor recruitment due to decreased chromatin relaxation at the site of damage.
Inhibition of transcription and the resulting reduction of repair factor protein levels could
be another general mechanism responsible for repair inhibition by actin binding compunds. To
measure overall transcriptional activity, nuclear run-on assay was performed. With this assay,
incorporation of 5-FU, which happens when transcription is ongoing, can be visualized by im-
munocytochemistry. Short term low dose treatment with both actin binders LB and Jaspla did
not decrease transcriptional activity (Fig. 15). It is therefore unlikely that DNA damage repair
is inhibited due to general inhibition of transcription of proteins involved in DDR upon low dose
treatment with actin binding substances.
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Figure 15: Low dose treatment with actin binders does not inhibit overall transcriptional activity.
HeLa cells were treated with LB or Jaspla for 2h. Treatment with actinomycin (7.5µg/ml) served
as positive, DMSO treatment as negative control. 5-FU was added, cells fixed, permeabilized and
stained for incorporated nucleotid analogons (anti-BrdU antibody). Percentages of positive cells
were calculated (mean values +/- SEM). At least 150 cells were analyzed for each condition in three
independent experiments.
4.1.5 Actin manipulation does not inhibit activation of the ATM-Chk2 pathway
and phosphorylation of histone H2AX.
The detection of DNA DSB by MRN leads to activation of numerous signalling cascades. MRN
phosphorylates and thereby activates for instance ATM which subsequently activates Chk2. The
ATM-Chk2 pathway is involved in many DNA damage induced processes, such as DNA repair,
cell cycle arrest or apoptosis induction [24, 26]. The activation of the ATM-Chk2 pathway can be
evaluated through phosphorylation levels of both members at Ser1981 and Thr68, respectively,
as these represent activating phosphorylation sites. To test if the inhibition of DNA damage
repair by different actin binders is caused by a reduced activation of the ATM-Chk2 pathway,
initiation of phosphorylation at both activating sites upon DNA damage induction was mea-
sured by western blot (Fig. 16). However, no reduction in phosphorylation by addition of LB,
Jaspla or ChB could be observed. Phosphorylation of ATM was even significantly increased when
treated with LB or Jaspla. Actin binders alone did not induce phosphorylation of ATM or Chk2.
MRN also phosphorylates histone H2AX adjacent to the break which functions as a scaffold
for many proteins involved in DNA damage repair [28, 29]. Foci formation by phosphorylation
of surrounding H2AX can be visualized by immunocytochemistry. After DNA damage induction
with Doxo, a strong increase in cells positive for yH2AX could be detected, which was not sig-
nificantly impeded by additional application of the actin binding substances LB or Jaspla (Fig.
17A). Combination treatment with LB only led to a small decrease in cells positive for yH2AX
foci formation. Flow cytometry analysis was performed to measure chromatin association of
yH2AX (Fig. 17 B) and western blot to determine phosphorylation of H2AX (Fig. 17C). The
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Figure 16: Phosphorylation of ATM and Chk2 upon Doxo induced DNA damage. HeLa cells were
treated with Doxo alone or in combination with the indicated substances for 1h. Cells were harvested
and lysed and immunoblotting performed. Tubulin served as loading control. Values were calculated
with ImageLab, normalized on untreated control (n=3, values +/- SEM). One blot out of three
independent experiments is depicted as an example. A ATM. Phosphorylation at Ser1981. One-
way ANOVA, Dunetts multiple comparisons test * p<0.05, ** p<0.01. B Chk2. Phosphorylation
at Thr68.
slight reduction of yH2AX foci numbers upon LB combination treatment (as shown in Fig. 17A)
could not be confirmed with these methods.
In summary, actin binders did not impair phosphorylation of ATM, Chk2 and histone H2AX.
An inhibition of early phosphorylation events was therefore not considered to be the cause of
decreased DNA DSB repair by actin manipulation.
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Figure 17: Actin binders do not decrease phosphorylation of histone H2AX upon Doxo induced
DNA damage. A yH2AX foci formation. Cells were treated with Doxo alone or in combination
with the depicted actin substances for 2h, cells fixed and stained for yH2AX, nuclei (Hoechst) and
the cytoskeleton (rhodamine). Examples are shown on the left. Cells with more than 5 foci were
defined as positive and the percentage of positive cells calculated. Graph on the right shows mean
values (+/- SEM) of three independent experiments (unpaired t test, ns not significant). B yH2AX
chromatin association. HeLa cells were treated with the indicated substances for 2h. Unbound
protein was excluded by washing with extraction buffer, cells fixed with 4% PFA and stained for
yH2AX and flow cytometry performed (n=3). C yH2AX protein level. HeLa cells were treated
with Doxo and the indicated actin binders for 1h. Cells were harvested, lysed and immunoblotting
performed. Tubulin served as loading control. Values were calculated with ImageLab, normalized on
control (untreated). One exemplary blot out of three experiments is shown.
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4.1.6 Actin binders inhibit distinctive DSB repair pathways.
Distinctive repair pathways are activated upon DSB induction. The choice between non-homologous
end joining (NHEJ), alternative end joining (alt-EJ), homology directed repair (HDR) and sin-
gle strand annealing (SSA), primarily depends on the cell cycle state of the cell. To study DNA
damage repair capacity in detail, I-SceI-based reporter cell lines that can distinguish between
all four DSB repair pathways have been developed (published in [120] and described in detail
in 3.2.3.3). Transient overexpression of the endonuclease I-SceI leads to cuts in specific GFP
cassettes that are interrupted by one or more I-SceI recognition site(s). The repair of I-SceI
induced breaks results in a rescue of GFP expression. GFP-positive cells can then be measured
by flow cytometry.
Treatment with actin binders after induction of DSB by transient I-SceI expression led to dif-
ferential responses (Fig. 18). Both actin polymerizers Jaspla and ChB inhibited NHEJ, whereas
LB did not reduce NHEJ capacity (Fig. 18A). Alternative end joining was not influenced by any
of the applied actin binding substances (Fig. 18B). On the contrary, the impairment of both
pathways HDR (Fig. 18C) and SSA (Fig. 18D) did not depend on the type of actin manipulation
and was significant for both LB and Jaspla.
Figure 18: Effects of actin manipulation on distinctive DSB repair pathways. U2OS cells expressing one
of each respective reporter system were transfected with pcBASE (overexpression of I-SceI) and then
cultivated with or without the indicated actin substances (LB [500nM], Jaspla [50nM], ChB [75nM])
for 72h. Percentages of GFP-positive cells were measured by flow cytometry. Experiment performed
in duplicates. Mean values of three independent experiments are shown (+/- SEM), unpaired t test,
one-tailed, * p<0.05, ** p<0.01, *** p<0.005. A NHEJ. Non-homologous end joining. B Alt-EJ.
Alternative end joining. C HDR. Homology directed repair. D SSA. Single strand annealing.
In summary, actin binding substances inhibit specific pathways that play a role in the repair
of Doxo induced DSBs.
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4.1.7 Ku70 binds to nuclear actin and actin binders decrease activation of
DNA-PK.
DSB repair by non-homologous end joining was inhibited by increased actin polymerization
due to Jaspla and ChB treatment (as shown in Fig. 18A). One of the key events for NHEJ
initiation is the activation of DNA-PK, which is induced by the recruitment of DNA-PKcs (cat-
alytical subunit) to DNA-bound Ku70/80. Its kinase activity is further elevated by numerous
auto-phosphorylation events [40, 41]. Activation of DNA-PK can therefore be correlated with
increased phosphorylation of specific sites.
Doxo induced autophosphorylation of DNA-PK (pDNA-PK) at T2609 was decreased after
treatment with Jaspla or ChB, as displayed by a reduction of pDNA-PK foci in the nucleus.
Inhibition of DNA-PK autophosphorylation by ChB was significant after a short term treatment
of two hours (Fig. 19A). The slight effects of Jaspla on phosphorylation after two hours were
further increased after four additional hours of repair time (Fig. 19A+B). LB treatment showed
only weak effects on DNA-PK autophosphorylation (Fig. 19A).
Figure 19: Autophosphorylation of DNA-PK (T2609). HeLa cells were treated with Doxorubicin with or
without additional actin substance treatment for 2h. For measurements without repair time, cells
were then fixed, permeablized and immunocytochemistry performed. For measurements with repair
time, Doxorubicin was removed after 2h and cells incubated in DMEM +/- Jaspla (4h repair time)
followed by fixation and permeabilization. Foci were visualized by antibody staining against pDNA-
PK (T2609). Foci were counted with FiJi Plugin FindFOCI GUI. Cells with at least 70 foci per
nucleus were determined as strong positive cells and percentages calculated. At least 100 nuclei were
analyzed for each sample (n=3, unpaired t test, one-tailed, * p<0.05). A No repair time. B 4h
of repair time. Graph on the left shows single values of foci numbers per nucleus for all conducted
experiments, graph on the right depicts mean values of percentages of strong positive cells.
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The observed reduction of phosphorylation events at T2609 was not caused by decreased pro-
tein levels of total DNA-PKcs (Fig. 20A) or Ku70 (Fig. 20B).
Figure 20: DNA-PK protein levels. A DNA-PKcs. HeLa cells were treated with Doxo [1µM] and/or
the indicated actin binders (LB [1µM], Jaspla [100nM], ChB [100nM]) for 1h. Cells were harvested
and lysed followed by immunoblotting. Tubulin served as loading control. One blot out of three
independent experiments is depicted. B Ku70. HeLa cells were treated with the indicated substances
(Doxo [250nM], LB [500nM], Jaspla [100nM]) and immunoblotting performed for detection of Ku70
and actin. One exemplary blot is shown.
Furthermore, DNA-PKcs was not bound to nuclear actin before or after DNA damage in-
duction, indicated by the lack of positive events in a proximity ligation assay (Duolink R©) (Fig.
21B). Functionality of the applied DNA-PKcs antibody was confirmed with control immunocy-
tochemistry (Fig. 21A). Thus, obstructed binding of nuclear actin to DNA-PKcs was considered
not to be the cause of reduced DNA-PKcs autophosphorylation at T2609. Autophosphoryla-
tion of DNA-PKcs is induced upon binding to DNA-bound Ku [40, 41]. The observed decrease
of phosphorylation could therefore also be caused by altered recruitment of Ku to the DNA.
Duolink assay revealed that indeed Ku70 seems to be bound to nuclear actin under control
conditions (Fig. 21C). This binding was slightly reduced after induction of DNA damage (Fig.
21C1). Hyperpolymerization of actin by overexpression of the actin mutant S14C led to a de-
creased binding of Ku70 to nuclear actin, whereas depolymerization upon G13R overexpression
did not show any effects (Fig. 21C2).
52
4 Results
Figure 21: Interaction of nuclear actin and DNA-PK. A Control staining. HeLa cells were fixed,
permeabilized and stained for DNA-PKcs or Ku70 and Hoechst to ensure functionality of the applied
antibodies. B Binding of nuclear actin to DNA-PKcs. HeLa cells were treated with Doxo
[250nM] for 2h and Duolink assay (Duolink reagents GREEN) performed. Antibodies against actin
and DNA-PKcs were used (nuclear area is shown and nuclear outlines highlighted in white). C
Binding of nuclear actin to Ku70. Antibodies against actin and Ku70 were applied. C1 HeLa
cells were treated with Doxo [250nM] for 2h and Duolink assay (Duolink reagents GREEN) performed.
Nuclear events were counted manually. Outlines of nuclei are shown in white. Mean values of four
experiments are shown, *p>0.01, unpaired t test, one-tailed. C2 HeLa cells were transfected with the
indicated plasmids and Duolink assay (Duolink reagents RED) performed. Nuclei were stained with
Hoechst (blue). Nuclear events were counted manually. Mean values of three independent experiments
are shown, values normalized on control.
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4.1.8 Nuclear actin is bound to RPA and is involved in its recruitment to the site
of damage.
Interestingly, HDR and SSA were affected by actin manipulation, whereas alt-EJ was not. There-
fore, key mediators of HDR and/or SSA that specifically play a role in one or both of these
pathways but not in alt-EJ can be the cause for differential responses to treatment with actin
binders. One key player in HDR and SSA is RPA (Replication Protein A). RPA binds to ssDNA
and protects DNA ends from degradation preventing spontaneous annealing between microho-
mologies (inhibits alt-EJ). Successful recruitment of RPA to the site of damage and its chromatin
association is required for both HDR and SSA [127].
Recruitment of RPA-2 to DSBs was diminished upon combination treatment with LB and
Jaspla, indicated by a significant decrease in the number of RPA-2 foci in the nuclei (Fig. 22A)
and a reduced chromatin association of RPA-2 upon DNA damage induction (Fig. 22B). LB was
found to be more efficient than Jaspla in the short term inhibition of RPA-2 recruitment with
the tested substance concentrations (Fig. 22B).
To assess whether actin regulates recruitment by direct (or indirect) interaction with RPA-
2, proximity ligation assay was performed (Duolink R©). Indeed, actin was found to be bound
to RPA-2 in the nucleus under control conditions. The number of positive events (i.e. actin
molecules that are bound to RPA-2) decreased significantly upon Doxo treatment, suggesting
a release of RPA-2 from actin when DNA damage was induced (Fig. 23A). Reduced events
were also observed after short term treatment of cells with either LB or Jaspla (Fig. 23A). The
suggested interaction of RPA-2 and nuclear actin could be verified by co-immunoprecipitation.
Under control conditions, actin was bound to precipitated RPA-2 and the interaction was de-
creased upon damage induction and actin manipulation by LB (Fig. 23B). Hyperpolymerization
of actin by overexpression of mutant actin (S14C) decreased binding of actin to RPA, whereas
reduced polymerization of actin (G13R) slightly increased the number of positive events (Fig.
23C). Binding of RPA-2 to nuclear actin might thus depend on the state of actin, and an increase
in G-actin monomers might favor the interaction of actin and RPA-2.
Treatment with actin binders and/or Doxo did not alter protein levels of RPA-2 (Fig. 24).
The above observed reduction in the detected interaction of actin and RPA-2 was therefore not
caused by decreased protein quantities.
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Figure 22: Recruitment of RPA-2 to the site of DSB. A RPA foci formation. HeLa cells were treated
with Doxo with or without additional actin substance treatment for 2h. Doxo was then removed
and cells incubated in DMEM (repair time 4h) +/- actin substances. RPA-2 foci were visualized
by antibody staining. Nuclear RPA-2 foci of positive cells were counted with FiJi Plugin FindFOCI
GUI. Numbers of foci were normalized on nuclear area to exclude variances due to changing nuclear
sizes. At least 25 nuclei were analyzed for each sample and experiment (mean values +/- SD, n=3,
unpaired t test, two-tailed, **** p<0.0001). B Chromatin association of RPA-2. After treatment
with Doxo alone or in combination with the indicated actin substances for 2h, cells were harvested.
Free RPA was extracted by washing with extraction buffer, cells fixed, stained for RPA-2 and flow
cytometry performed. Mean values of three experiments are shown (+/- SEM), unpaired t test one-
tailed, ** p<0.01.
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Figure 23: Binding of RPA-2 to nuclear actin is decreased upon DNA damage induction and actin
manipulation. A DuolinkR© assay. HeLa cells were treated with Doxo +/- the indicated actin
substances and Duolink assay (GREEN) performed with antibodies recognizing RPA-2 and actin,
respectively (upper line). To ensure specificity of the applied antibodies, control stainings with only
one antibody were performed (lower line). Positive events were normalized on numbers of control
cells (mean values +/- SEM). At least 250 cells were analyzed for each treatment condition. Outlines
of nuclei are shown in white. One-way ANOVA, Sidaks multiple comparisons test, * p<0.05, **
p<0.01, ns not significant. B Co-immunoprecipitation. HeLa cells were treated with the indicated
substances. Protein samples of nuclear extracts were immunoprecipitated with RPA-2 antibody and
immunoblotted for actin and RPA-2. 4% of each nuclear lysate was used for preparation of input
samples. One exemplary blot is depicted. Band densities were quantified and calculated as a ratio
of actin intensity to RPA-2. Graph shows mean values normalized on control. C DuolinkR© assay.
HeLa cells were transfected with the indicated actin plasmids and Duolink assay (RED) performed.
Positive events were counted in three independent experiments (mean values +/- SEM) with at least
150 cells for each transfection condition.
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Figure 24: RPA-2 protein levels. HeLa cells were treated with Doxo and/or the indicated actin binders for
1h. Cells were harvested and lysed followed by immunoblotting. Stain-Free gel served as loading
control. One blot out of three independent experiments is depicted.
Diminished chromatin association of RPA-2 upon DNA damage induction is therefore likely
caused by obstructed recruitment resulting from actin manipulation. The finding that RPA-2 is
bound to nuclear actin and released upon damage induction indicates a direct involvement of
actin in the recruitment process of RPA-2.
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4.2 Actin as a potential target for combination chemotherapy
Despite its severe side effects, application of Doxo for chemotherapy is nevertheless still widely
used in the clinics as one of the most potent chemotherapeutics [17, 19]. The formulation of
combination therapy concepts is considered a promising approach to diminish unwanted side
effects during therapy with Doxo while still exploiting its anti-tumoral activities. So far, actin
binders have mainly been described as potential substances for single chemotherapy in different
experimental setups, both in vitro and in vivo (as described in 2.2.3). However, since actin
manipulation was found to impair nuclear DNA damage repair processes, the combination of
actin binders with a DNA damage inducing chemotherapeutic such as Doxo represents a new
possibility for combination cancer therapy.
4.2.1 Latrunculin B inhibits cancer cell proliferation in combination with
doxorubicin.
The potential application of actin binders for combination treatment with Doxo was tested in
two different cancer cell lines. Both metabolic activity (Fig. 25A) and colony formation abil-
ity (Fig. 25B) were decreased when Doxo treatment was combined with LB in HeLa and T24
cells, whereas Jaspla treatment could not further inhibit proliferation. Single treatment with
actin binders only slightly affected proliferation. The reduction of proliferation by additional
application of LB was in both assays synergistic in HeLa cells (Bliss value 1.305 and 1.789 for
metabolic activity and colony formation, respectively). This observed blockage of proliferation
could be partially attributed to an induction of cell death in HeLa cells (Fig. 25C). In T24 cells
a synergistic increase in apoptotic cells was detected (Bliss value 1.746) (Fig. 25D).
In summary, combination treatment of Doxo with LB led to decreased proliferation and in-
creased apoptosis induction in both tested cancer cell lines compared to single Doxo treatment.
Low dose Jaspla treatment could not further diminish proliferation when combined with Doxo.
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Figure 25: Effects of combination treatment on cell viability and cell death induction. HeLa and
T24 cells were treated with the indicated actin substances in combination with Doxo. Graphs show
mean values (+/- SEM) of three experiments, unpaired t test, one-tailed, * p<0.05, ** p<0.01, ns
not significant. A Metabolic activity. Cell titer blue assay was performed after 72h of treatment.
B Colony formation. HeLa and T24 cells were treated for 2h and then seeded in 6-well plates in
new DMEM medium, without any substances. After 6 days of growth, total area was determined
using the ImageJ plugin ColonyArea and normalized on control values. C Cell death induction.
HeLa cells were treated for 48h, then fixed with methanol and stained with 7-AAD. Dead cells were
determined by the subG1 gate. D Apoptosis induction. T24 cells were treated for 72h hours,
followed by YoPro staining without prior fixation and percentage of apoptotic cells was evaluated.
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4.2.2 Latrunculin B impairs DNA damage repair in vivo.
As described above, LB was found to inhibit proliferation synergistically in vitro when combined
with Doxo. To prove if DNA repair inhibition by additional treatment with actin binders can also
be achieved in vivo, a xenograft tumor model with 4T1 cells (murine breast cancer) was designed.
First in vitro tests showed that DNA DSB repair was inhibited after actin manipulation, com-
parable to the effect observed in HeLa cells (Fig. 26A). Under low dose treatment conditions,
the extent of inhibition was higher in LB treated cells compared to Jaspla. Furthermore, LB
was tolerated well in mice if injected i.p. and could be combined with i.v. Doxo treatment (Fig.
26B). To assess the effect of LB on DNA damage repair in vivo, 4T1-tumors bearing mice were
injected i.v. with Doxo alone or in combination with LB (i.p.) for 24h followed by tumor cell
isolation. Comet assay was performed to evaluate the extent of damaged DNA in isolated tumor
cells. In established tumors, additional application of LB led to a significant increase in damaged
DNA compared to single Doxo treatment, whereas LB alone did not induce DNA damage (Fig.
26C).
LB can thus inhibit DNA damage repair in established tumors in vivo at tolerable substance
concentrations leading to an increase of chemotherapy induced DNA damage.
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Figure 26: Effects of latrunculin B on DNA damage repair in vivo. A In vitro alkaline comet assay.
4T1 cells were treated with 250nM Doxo for 2h with or without addition of the respective actin
substance. Cells were then incubated in DMEM or DMEM + actin substance. Doxo treatment alone
without repair time served as positive control. Images were analyzed with OpenComet (ImageJ) and
tail moments calculated. Relative tail moment is shown (tail moments normalized on doxo repair
samples). Mean values (+/- SEM) of at least three independent experiments are depicted (one-way
ANOVA, *p<0.05). B Toxicity test in vivo. Mice were treated with the indicated substance
concentrations and mouse weight observed for up to 48h (n=2). Performed by Carina Atzberger and
Kerstin Loske. C In vivo alkaline comet assay. Mice were injected with 1x106 4T1-luc cells and
tumors grown for 7-9 days. Mice were then treated with 3mg/kg doxo (i.v.) with or without additional
LB treatment (0.1mg/kg, i.p.) for 24h. Mice treated i.v. with PBS and i.p. with PBS + 5%DMSO
+ 10%solutol served as negative control. Tumors were harvested, digested enzymatically and single
cell suspensions used for alkaline comet assay (C1). Tail moments were analyzed with OpenComet.
One exemplary picture for each condition is shown on the left. Graph shows relative tail moments
(normalized on control samples) and mean values of 11 mice per sample ((one-way ANOVA, *p<0.05)
(C2). Tumor cell injection and treatment of mice carried out by Carina Atzberger and Kerstin Loske.
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5.1 The role of nuclear actin in DNA double strand break repair
In this work, the role of actin in nuclear DNA repair signalling and the influence of actin
manipulation on DSB repair pathways were elucidated. Treatment with actin binders led to
inhibition of specific processes during different pathways, resulting in inhibition of HDR, SSA
and NHEJ, while alt-EJ was not influenced. These results provide new proof that actin is directly
involved in nuclear processes during DNA damage repair signalling.
5.1.1 Can actin be polymerized in the nucleus?
In 2006, McDonald et al. provided the first experimental evidence that actin polymers exist in
the nucleus [81], and that nuclear functions of actin might thus indeed be controlled by poly-
merization and depolymerization. Polymerization of nuclear actin has been described to occur
upon DNA damage induction and to be required for functioning of DNA repair upon radiation
[79, 113]. Visualization of filamental actin, especially in the nucleus, is technically challenging.
It is thus difficult to determine the exact state of nuclear actin. All nowadays applied tech-
niques hold pitfalls. Although classical F-actin marker phalloidin shows a very high specificity
to filamental actin, it only binds to filaments of at least 7 monomers and specific APBs, such
as Cofilin, can compete with phalloidin binding. Phalloidin is therefore not able to visualize all
kinds of actin filaments and cannot be used to detect actin oligomers. It can also be applied only
in fixed samples. For life cell imaging, fluorophore-tagged actin can be overexpressed to analyze
actin dynamics in living cells. But tags, such as GFP, might perturb actin functions due to steric
hindrances and changes in physiological actin levels. Nuclear actin can be visualized by overex-
pression of the nuclear actin-Chromobody (ChromoTek), a nanobody that is directed against
actin and harbors a GFP-tag and a NLS sequence. However, overexpression of an actin binding
antibody with a NLS might alter nuclear actin levels and stabilize actin structures (reviewed
in [123]). Actin binders have been reported in general to induce polymerization in specific cell
compartments, especially in the nucleus [128]. This was also true for treatment with the sub-
stances applied in this thesis and could, at least partly, be due to induced stress responses upon
sensing of changes in overall actin states.
Nevertheless, the observation of actin filaments/agreggates upon damage induction when chro-
mobody was overexpressed (as described in this thesis and in [79]) indicates that reorganization
of actin in the nucleus is important for the activation or maintenance of signalling pathways
involved in DNA repair. The decrease of free actin measured by FCS and the lack of actin-GFP
export from the nucleus strengthen the hypothesis that actin polymerization occurs upon DNA
damage induction. Visible actin aggregates could only be detected when damage induction was
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performed after transfection of cells with the nuclear actin chromobody, indicating that the over-
expression of the NLS-tagged antibody really stabilizes actin structures and thereby exaggerates
the observed effect. Most likely, polymerization of actin due to DNA damage induction rather
leads to oligomers instead of long filaments or larger aggregates and thus cannot be visualized
by standard fluorescence microscopy.
Actin binders have shown different effects on nuclear actin organization. Although LB in-
creased and Jaspla decreased nuclear actin levels, both led to formation of nuclear actin agreg-
gates/filaments. Cofilin-dependent translocation of actin into the nucleus upon LB treatment
has been described in rat peritoneal mast cells [84] and might be a general response to actin
depolymerization, also in cancer cells. Cofilin is an important nuclear import factor of actin and
the formation of nuclear cofilin-actin rods upon stress signals has been described [80, 84, 85].
The observed decrease in nuclear actin levels by Jaspla could arise due to a direct induction
of actin export but also through an inhibition of the actin import to the nucleus. Differential
changes in the nuclear actin levels upon actin binder treatment could therefore be explained by
opposing effects on the active cofilin-dependent import of actin. This explanation seems more
likely than effects on the profilin-dependent export [86], as LB did not impede profilin binding
(unpublished data) and Jaspla binds to filamental actin and is thus not expected to directly
obstruct the binding of a G-actin binding partner. Aggregation of actin in the nucleus due to
LB treatment could be explained by spontaneous polymerization due to increased actin pro-
tein levels if the level of physiological depolymerizers cannot be adjusted fast enough. Again,
nuclear actin filament formation was only observed when actin binder treatment was combined
with Chromobody overexpression, and might therefore be, at least partially, an experimental
artefact. In any case, if nuclear actin is important for DNA repair, deregulation of actin states
by treatment with actin binding substances will likely influence actin-dependent DNA damage
signalling.
It is still not understood how the polymerization of actin functions in the nucleus and how it
is triggered upon stress signals. Actin nucleators from different classes have been found in the
nucleus but there is no direct proof so far that they are also able to induce actin nucleation
and subsequent formation of nuclear actin filaments (reviewed in [82]). Belonging to the class
1 NPFs (nucleation-promoting factor), N-WASP and its activator NCK1 can for example be
localized in the nucleus. Upon UV-induced DNA damage, NCK1 translocates to the nucleus
in association with SOCS7 (suppressor of cytokine signalling 7) and G-actin [129]. Another
example is JMY, an actin nucleator which activates the Arp2/3 complex and also nucleates
actin filaments independently of Arp2/3. DNA damage mediated polymerization of cytoplasmic
actin leads to import of JMY to the nucleus, where it is for instance involved in p53 activation
[130]. Translocation of actin nucleators to the nucleus upon DNA damage induction might
therefore be responsible for actin oligomerization or even polymerization, although this is still
only a hypothesis. In addition, the existence of actin binding proteins like profilin, cofilin and
gelsolin in the nucleus imply a tight regulation of the state of nuclear actin [131].
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5.1.2 Actin manipulation inhibits specific DNA damage repair pathways
The observation that actin manipulation leads to impairment of DSB repair raised the question
in which DDR associated processes actin is involved.
Phosphorylation of ATM is an important step in DNA repair as it triggers the activation of
many different substrates, such as Chk2 and H2AX, that are involved in DNA repair, cell cycle
arrest and apoptosis induction. The activation of the ATM-Chk2 pathway was not impeded by
actin manipulation and phosphorylation levels of both members were even slightly increased.
Phosphorylation of H2AX is involved in early DSB signalling. However, loss of H2AX only leads
to mild phenotypes in mice regarding DNA damage repair capacity [132]. Nevertheless, it is
often used as a biomarker for damaged DNA [32, 33]. Latrunculin A has been reported by Leu
et. al to inhibit yH2AX foci formation upon irradiation [112], an effect not observed by LB in
this work. This might be explained by the high doses that were applied in the study of Leu
et. al, which could have induced unspecific inhibition of signalling pathways due to cell death.
Although different DSB repair pathways were inhibited by actin binder treatment, yH2AX foci
formation was completely unaffected, indicating that yH2AX levels do not necessarily correlate
with the functioning of DSB repair pathways. Local relaxation of heterochromatin depends on
ATM-mediated phosphorylation of KAP-1 and is required for the recruitment of many repair fac-
tors to the DNA break [133]. The local decondensation of chromatin upon UV-induced damage
was not impeded by actin manipulation and the global chromatin structure was not significantly
changed. Low dose treatment with actin binding substances did not influence overall transcrip-
tional activity. General events, essential for induction of DNA damage repair, were therefore not
altered by application of actin binders. The inhibition of DSB repair by actin binding substances
seems thus more specific than one might expect.
Actin manipulation inhibited specific nuclear processes involved in DSB repair signalling. The
inhibition of HDR and SSA could be attributed to an impaired recruitment of RPA to the site
of damage. This also explains why alt-EJ was not influenced, as RPA works against this third
pathway. RPA can only be recruited to long stretches of ssDNA which are produced by extensive
DNA end resection. The available experimental protocols for the measurement of ssDNA in cells
were unfortunately not suitable for the quantification of short term induction of ssDNA upon low
dose Doxo treatment. A potential additional involvement of nuclear actin in processes important
for the formation of long ssDNA could therefore neither be validated nor negated. Nevertheless,
a direct connection between actin and RPA recruitment could be provided. Nuclear actin was
bound to RPA-2 under control conditions and released upon induction of DSBs, and the binding
was found to be favoured by an increased G-actin pool. Serebryannyy et al. suggested RPA-3
as a potential nuclear actin binding partner, displayed in mass spectrometry analyses following
a pulldown assay with purified non-muscle actin of nuclear HeLa extracts [114]. The proposed
interaction, however, has not been confirmed by the group. This study provides now the first
experimental proof that RPA (in this case subunit RPA-2) can bind to actin in the nucleus.
Actin hyperpolymerization by application of Jaspla or ChB led to inhibition of NHEJ which
could be connected to a significantly decreased activation of DNA-PK. LB treatment also led to
a slight reduction of DNA-PK phosphorylation. The missing effect of LB on the repair of I-SceI
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induced damage in the respective reporter cell line could be due to the experimental setup.
The repair efficacy was measured after 72h and LB can only affect the actin cytoskeleton for a
couple of hours (as shown in this thesis and in [106]). It can therefore not be concluded that
actin depolymerization has no effect on NHEJ signalling. Recruitment of Ku to the DNA is
critical for the formation and activation of DNA-PK. Ku70 was demonstrated to bind to actin
in a proximity ligation assay. These findings go in line with the published study of Andrin et
al., which showed that Ku binds to F-actin and that actin depolymerization leads to perturbed
retention of Ku80 at the DNA break [113]. Nuclear actin seems thus to be directly involved in
Ku recruitment to damaged DNA. The in this work observed reduction of positive events upon
DNA damage induction in the proximity ligation assay might be caused by an association of
protein complexes involving Ku and/or actin with chromatin. For a better understanding of the
exact mechanism further investigations are necessary.
5.1.3 How do actin binding substances influence repair factor recruitment?
An obstructed binding of nuclear actin to repair factors could on the one hand be explained
by a dependence on the state of actin, i.e. G-actin or F-actin, or on the other hand by a direct
replacement of actin binding partners by actin binding compounds.
Overexpression of mutant actin inducing nuclear actin hyperpolymerization decreased the
binding of RPA to actin, implying that the state of actin does play a role. RPA could be trapped
by monomeric actin in the nucleoplasm under physiological conditions and actin oligomeriza-
tion or polymerization might be necessary to release RPA, followed by recruitment to ssDNA
surrounding the break (as depicted in Fig. 27). Such a principle was described in the cytoplasm
for the actin binder JMY. In this case, JMY is bound to G-actin under control conditions and
released upon actin polymerization followed by a transport to the nucleus, where it enhances
the transcriptional activity of p53 [118, 119]. This type of process might thus not only happen in
the cytoplasm, but also in the nucleus. The potential actin hyperpolymerization in the nucleus
due to treatment with actin binding substances might lead to the release of RPA-2 from actin,
and thereby delivers RPA-2 at the wrong time point.
Figure 27: Model for actin dependent RPA recruitment to ssDNA. RPA recruitment to the site of DNA
damage might depend on the regulation of actin states in the nucleus. Under normal conditions RPA is
bound to G-actin in the nucleus. The occurence of DNA damage induces nuclear actin polymerization
and thereby releases RPA. Free RPA can then be recruited to ssDNA.
G-actin consists of a smaller and a larger domain which are further divided into subdomains
1 and 2 (smaller domain) and subdomains 3 and 4 (larger domain). The nucleotide binding
cleft (NBC) is located between subdomains 1 and 4 where a nucleotide - either ADP or ATP -
bound to a divalent cation can be positioned. The NBC is separated from the hydrophobic cleft,
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which represents the primary binding site for many ABPs [134]. Binding of ABPs can be favored
by different nucleotide states. Cofilin, for example, binds to ADP-bound actin, whereas profilin
prefers ATP-bound actin. Nucleotide-dependent conformational changes can occur and different
nucleotide-sensitive regions have been described, namely the DNAse binding loop (D-loop), the
WH2 binding loop (W-loop) and both the N- and C-terminal end of actin [134]. Binding of the
D-loop of one actin subunit to the hydrophobic cleft of a neighboring subunit can be regulated
by nucleotide hydrolysis and is thus predicted to be involved in contacts of actin-monomers
along the F-actin helix [135]. The W-loop is the prime interaction site for WH2 domain proteins
[134] and plays an important role in the binding of e.g. profilin [136] and cofilin [137].
LB binds in the nucleotide binding cleft of actin [138]. As nucleotide sensitive regions, im-
portant for the binding of specific ABPs, have been described, NBC obstruction could therefore
hinder binding of actin binding partners. LB might thus lead to allosteric inhibition of the bind-
ing of specific ABPs. Such an effect might in general rather depend on the exact binding site
than on the class of the actin binding compound. In this respect, LB for example does not impair
profilin binding to actin whereas Chivosazole A does (unpublished data).
Both phalloidin and Jaspla bind in the gap between two F-actin strands, or in other words
to the actin-actin contact sites at the interface of three actin subunits [139, 140]. Phalloidin
competes for example with nebulin [141] and gelsolin [142], suggesting that also Jaspla might
directly or indirectly displace ABPs or prevent them from being added.
Actin binding substances might therefore directly replace DNA repair factors from actin in
the nucleus, resulting in a blockage of recruitment to the DNA break. In the case of RPA, LB
might directly replace RPA-2 from G-actin (Fig. 28A). On the contrary, the reduction of G-
actin abundance by Jaspla treatment might indirectly decrease the interaction of RPA-2 and
actin (Fig. 28B). To unravel which DNA repair factors bind to actin and which ABPs could be
displaced by actin binding compunds, further extensive research is still needed.
Figure 28: Model for the displacement of RPA-2 from actin by actin binding compounds. A LB.
Binding of LB to G-actin directly inhibits the interaction of RPA-2 and nuclear actin. B Jaspla.
Jaspla stabilizes F-actin and thereby indirectly prevents the potential interaction of RPA-2 and
G-actin.
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5.2 Targeting actin for combination chemotherapy - should we bring
actin binding substances back into focus?
DNA damage inducing therapy is successfully used for cancer treatment, as extensive and per-
sistent DNA damage induces cell cycle arrest or cell death [143]. However, several problems
arise with this kind of tumor treatment. First, all rapidly proliferating cells will be targeted,
thus it is not a tumor tissue specific treatment. Secondly, in addition to killing the wrong cells,
it can lead to therapy-induced malignancies, as error-prone DNA repair pathways like NHEJ
will result in DNA mutations [22, 144]. As a consequence, classical chemotherapy often causes
severe side effects. The decrease of required substance concentrations by improvement of drug
delivery represents one approach to prevent unwanted secondary effects. To name one exam-
ple, pegulated liposomal doxorubicin (PLD) has been the first approved nanomedicine and is
nowadays used in breast cancer treatment. Its special formulation was designed to increase both
the stability of doxorubicin in the blood circulation and its selective release to the tumor tissue
(reviewed in [145]). However, PLD has not replaced free Doxo as a therapeutic option for all
indications, as several studies pointed out that PLD could not show higher anti-tumor activities
compared to each respective competitor (reviewed in [146]). The above mentioned problems are
therefore not (completely) solved yet. Another approach is the administration of combination
therapy. Inhibitors of specific factors important for DNA repair signalling have been developed
and are currently being tested for their potential application in cancer therapy. The evaluation
of combining DNA repair inhibitors with classical chemotherapy, however, represents an under-
investigated approach.
NHEJ is considered to be the main pathway responsible for rapid DSB repair after chemother-
apy [147] and represents thus one promising target for combination therapy. As one of the core
factors for functional NHEJ, DNA-PKcs can be targeted by different inhibitors that have been
developed recently. DNA-PKcs inhibition has been shown to sensitize for radiotherapy or top2
inhibitor treatment in vitro and in xenografts [148, 149]. The dual mTOR DNA-PKcs inhibitor
CC-115 has even been used for several preclinical phase I trials [23] (and clinicaltrials.gov). CC-
122, another DNA-PK inhibitor, has been tested for solid tumors, non-Hodgkin lymphoma and
multiple myeloma in a phase I clinical trial (NCT01421524) [150]. The most famous substance
is probably olaparib, the first FDA approved DNA repair inhibitor, which is currently being
tested in different contexts for combination therapy [21, 151]. Even though HDR is limited to
the S and G2 phase of the cell cycle, it is essential for the maintenance of genomic stability as
it not only repairs DSBs, but is also involved in the repair of both stalled and collapsed repli-
cation forks and interstrand crosslinks. Tumors with defects in HDR functions are described to
be highly sensitive to DSB inducing therapies and targeting HDR factors therefore seems to be
another attractive option for cancer therapy [23]. Different strategies to inhibit HDR have been
suggested, such as inhibition of Rad51 [152] or the interference with the ATM-Chk1/2 pathways
(reviewed in [23]). Although beneficial effects have been suggested in vitro and in preclinical
studies, the simultaneous combination of DNA damaging agents with DNA repair inhibitors is
not an established treatment option in the clinics yet.
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The inhibition of nuclear DSB repair pathways by application of actin binding substances
demonstrated in this work, proposes a new strategy for combination chemotherapy. Manipula-
tion of actin by different actin binding substances revealed inhibition, not only of one specific
repair factor, but of distinctive and separate DSB repair pathways. While designing treatment
strategies for cancer therapy, the following dilemma has to be faced: broad range therapeutics
(i.e. classical chemotherapy like Doxo) are very potent but generally not tumor-specific enough
and thus induce strong side effects, whereas highly specific therapeutics often lead to resistances.
On a long term basis, only a small subpopulation of cancer patients benefits from such a treat-
ment, due to the very heterogeneous nature of cancer [153]. Actin binding substances that inhibit
different DNA repair pathways simultaneously might thus represent a promising tool for cancer
therapy, as they specifically inhibit the repair of chemotherapy induced DNA damage targeting
several pathways that could otherwise fill in for each other. The effects of actin manipulation on
the functioning of DSB repair might, as a result, reduce the required concentration of Doxo. Syn-
ergistic effects of LB and Doxo in vitro and the increase in DNA damage when Doxo treatment
was combined with i.p. application of LB in vivo, as observed in this thesis, strongly support
this hypothesis. The reduction of Doxo concentrations would as a consequence be considered to
decrease the expected cardiotoxic side effects.
In general, the disruption of the cytoskeleton of malignant cells represents an ideal approach
for chemotherapeutic treatment, since malignant cells often exhibit a perturbed cytoskeleton
and are especially dependent on cytoskeletal functions due to their high proliferation rates [154].
However, all clinically approved cytoskeletal-directed substances inhibit the microtubule system,
whereas microfilaments or intermediate filaments are not targeted in the clinics (yet) (reviewed
in [155]). The functioning of the actin cytoskeleton is crucial for both proliferation and metasta-
sis formation, processes involved in the development of malignancies. However, severe side effects
are feared and actin binding substances have not been introduced to clinical investigations.
Not much has been published about actin binders in preclinical studies so far. Jasplakinolide
was soon dropped from consideration for clinical trials as it showed a very narrow therapeutic
index in rats and dogs when applied i.v. and lethality was accompanied by edema, hemorrhage
and congestion [156]. On the other hand, in mice bearing Lewis lung carcinoma, Jaspla has been
successfully applied i.p. and s.c. and led to tumor growth delay and sensitization to radiation
therapy [107]. The width of the therapeutic window might thus depend on how the substance
is administered. Cytotoxic effects of Jaspla have been described in human induced pluripotent
stem cell-derived cardiomyocytes in vitro, leading to a dose dependent decrease in viable cell
numbers and mitochondrial membrane potential and increase in membrane permeability [157].
The possibility of an even more pronounced cardiotoxicity would therefore have to be excluded
experimentally in vivo, although decreased substance concentrations in the combination ther-
apy might still lead to beneficial effects. In different in vitro proliferation assays performed for
this thesis, addition of Jaspla to Doxo treatment only led to slight effects on tumor cell pro-
liferation and colony formation ability. Further experiments are needed to determine the right
concentrations for both substances and the correct time points for pretreatment schedules for
the best results possible. Nevertheless, it can also be concluded that Jaspla is not a promising
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actin binding compound for further preclinical research.
Successful application of chondramide in vivo has been reported for i.v. and i.p. injection,
showing that chondramide treatment can be tolerated by mice [109, 158]. Additionally, in a
4T1-Luc BALB/c mouse model, premedication with chondramide led to reduced metastasis of
tumor cells to the lungs [109]. However, probably due to the negative report regarding Jaspla
treatment of rats and dogs, not many publications can be found about in vivo investigations
with the actin polymerizer chondramide. One important finding has to be mentioned, in which
chondramide induced caspase dependent apoptosis in breast cancer cell lines, whereas non-tumor
breast epithelial cells were found to be less sensitive to an apoptosis induction by chondramide
treatment. This suggests a tumor cell specificity of chondramide induced effects, even though a
universal protein such as actin was targeted [110].
Reports about the application of latrunculins are also rare. In this work it could be shown
that application of 0.1mg/kg LB i.p. is well tolerated in mice and increases the extent of Doxo
induced DNA damage. The additionally observed positive effects in combination with Doxo for
inhibition of tumor cell growth in vitro in two different cancer cell lines highlight the potential
of LB in combination therapy with DNA damaging agents.
In addition to a reduction of the required Doxo concentration, DNA repair inhibition through
application of actin binding substances can be achieved by concentrations lower than the ones
required for anti-cancer effects by actin binder monotherapy. The above described issue of the
narrow therapeutic window of actin binders in vivo might then not be a major problem anymore.
The improvement of drug delivery to the site of interest could further decrease feared side effects.
One possibility could be the application of nanotechnology based carrier systems, which would
allow the directed transport of actin binding substances to the tumor (e.g. [159]). Moreover,
photoresponsive conjugates of actin binders would allow local activation of the substance only
in the tumor (the feasibility of this approach has been published in [160]). Hence, there is still a
lot of room for future research to further enhance the efficacy of actin binder treatment in order
to reduce or even prevent possible remaining side effects.
The extent of potential positive effects of actin binder treatment in addition to Doxo likely
depends as well on the cancer type and its specific characteristics. The increased phosphoryla-
tion of both ATM and Chk2 after combination treatment with Doxo and actin binders indicates
an increased activation of the ATM-Chk2 pathway which is involved in p53-mediated induction
of apoptosis. In this work, HeLa cells were used for most of the experiments, a HPV infected
cell line which harbors inactivated p53 [161]. P53 dependent induction of cell death can thus
not occur. This suggests a testing of combination treatment with p53 wild type cancer cells, as
the synergism might strongly increase. This hypothesis is further supported by the finding that
F-actin negatively regulates translocation of p53 to the nucleus upon damage induction [117]. A
decrease of polymerized actin in the cytoplasm by treatment with actin depolymerizers like LB
might further enhance the synergistic effect of actin manipulation and Doxo treatment. On the
other hand, latrunculin A has been reported to reduce JMY-mediated p53 activation upon DNA
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damage induced cytoplasmatic actin polymerization [162]. It is therefore difficult to predict the
outcome of such a treatment in different cancer cell lines and further experiments would be
needed. Hyperactivation of ATM as a feedback to DNA-PKcs inhibition has been published and
amplified the p53 response to damage, thereby sensitizing the cells to damage induced senescence
[163]. In this work, ATM-Chk2 phosphorylation was shown to be induced which could therefore
(at least partially) be due to the decreased autophosphorylation (i.e. inactivation) of DNA-PK
upon actin manipulation. This underlines again that p53 wildtype cancer cells might be even
more susceptible for Doxo + actin binder combination treatment. Furthermore, highly motile
cancers with a high metastatic potential might be more susceptible to an additional targeting of
actin, since they strongly depend on cytoskeletal functions. In that case, even low dose treatment
with actin binders will still inhibit the actin cytoskeleton to a certain degree.
In summary, the inhibition of DSB repair by application of actin binding substances, such as
Jaspla and LB, proposes a new approach for combination chemotherapy. Especially the actin
depolymerizer LB showed promising results as it was well tolerated in mice, while increasing
DNA damage levels in combination with Doxo in vivo and decreaing proliferation when combined
with Doxo in vitro. Actin binding substances should thus definitely be brought back into focus,
as they show a high potential in the development of new cancer treatment strategies.
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5.3 Summary and conclusion
In this work, specific roles of nuclear actin in the repair of chemotherapy induced DNA DSBs
could be demonstrated (summarized in Fig. 29). Application of the actin binding substances
Jaspla and LB inhibited both HDR and SSA by impairing the recruitment of RPA to the site
of DNA damage. RPA-2 was demonstrated to be bound to nuclear actin and the impaired RPA
recruitment was hypothesized to be caused by an altered interaction of RPA-2 and nuclear actin.
Additionally, actin hyperpolymerization led to reduced activation of DNA-PK, resulting in an
inhibition of NHEJ. A fourth DSB repair pathway, alt-EJ, was not influenced by actin manipu-
lation. Due to the observed inhibition of DNA repair, actin binding substances were evaluated
as potential candidates for combination therapy with the DNA damaging agent Doxo. Addition
of LB to Doxo treatment synergistically inhibited proliferation in two different cancer cell lines
in vitro and increased DNA damage levels in tumor cells in vivo.
In conclusion, the successful utilization of actin binding substances in combination therapy
could be linked to the inhibition of Doxo induced DSB repair, thus presenting a novel treatment
approach for cancer therapy.
Figure 29: Effects of actin binders on DSB repair. During DSB repair, actin manipulation obstructs RPA
loading to ssDNA and thereby inhibits HDR and SSA, and decreases auto-phosphorylation of DNA-
PK for NHEJ, whereas alt-EJ is not influenced.
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7 Appendix
7.1 Abbreviations and units
Table 15
Abbreviation Meaning
ad. Fill up to
A Ampere
ABP Actin-binding protein
Alt-EJ Alternative end joining
ANOVA Analysis of variance between groups
ATM Ataxia-telangiectasia mutated
ATP/ADP Adenosine triphosphate/diphosphate
ATR ATM- and RAD3-related
bp base pair
BSA Bovine serum albumine
◦C Degree Celsius
ChB Chondramide B
Chivo Chivosazole A
Chk2 Checkpoint kinase 2
CM Complete media
Co-IP Co-immunoprecipitation
cs Catalytical subunit
CtIP C-terminal binding protein 1 (CtBP1) interacting protein
Da Dalton
DDR DNA damage response
DMEM Dulbeccos Modified Eagle Medium
DMSO Dimethyl sulfoxide
DNA Deoxyribonucleic acid
DNA-PK DNA-dependent protein kinase
Doxo Doxorubicin
ds Double stranded
DSB DNA double strand break
ECL Enhanced chemical luminescence
EDTA Ethylenediaminetetraacetic acid
e.g. For example
EXO1 Exonuclease 1
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Table 15: continued from previous page
Abbreviation Meaning
et al. And others
F-actin Filamental actin
FACS Fluorescence-activated cell sorting
FCS Fetal calf serum
FCS Fluorescence correlation spectroscopy
Fig. Figure
FSC Forward scatter
g Gram
G-actin Globular actin
GFP Green fluorescent protein
G-phase Gap phase
h Hour
HDR Homology derived repair
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HRP Horseradish peroxidase
i.e. Id est (that is)
i.p. Intraperitoneal
i.v. Intravenous
Jaspla Jasplakinolide
k 1000 (number)
kg Kilogram
Ku Ku70/80 heterodimer
l Liter(s)
LB Latrunculin B
m Milli / meter
M Molar
min Minute(s)
Miu Miuraenamide A
n Nano
NBC Nucleotide binding cleft
NHEJ Non-homologous end joining
p Phosphorylated
PBS Phosphate buffered saline
PARP Poly (ADP-ribose) polymerase
Pen/Strep Penicillin-Streptomycin
PMSF Phenylmethanesulfonylfluoride
PVDF Polyvinylidene difluoride
RNA Ribonucleic acid
ROS Reactive oxygen species
rpm Revolutions per minute
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Table 15: continued from previous page
Abbreviation Meaning
RPMI Roswell Park Memorial Institute
RT Room temperature
s Second(s)
s.c. Subcutaneous
Ser Serine
ss Single stranded
SSA Single strand annealing
S-phase Synthesis phase
SD Standard deviation
SDS Sodium dodecylsulfate
SEM Standard error of the mean
SSC Sideward scatter
T Threonine
Tab. Table
TBS-T Tris-buffered saline and Tween 20
TE Trypsin-EDTA
top2 Topoisomerase 2
Tris Tris(hydroxymethyl)aminomethane
UV Ultraviolet
V Volt
w/v Weight per volume
yH2AX Phospho-histone H2AX
µ Micro
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7.2.1 Original publications
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Herzog J, Ehrlich SM, Pfitzer L, Liebl J, Fro¨hlich T, Arnold GJ, Mikulits W, Haider C,
Vollmar AM, Zahler S.
Oncotarget. 2016, May 10.
Targeting actin inhibits repair of chemotherapy induced DNA damage: a novel
therapeutic approach for combination therapy
Pfitzer L, Moser C, Foerster F, Atzberger C, Zisis T, Kubisch-Dohmen R, Busse J, Smith R,
Timinszky G, Kalinina O, Wagner E, Vollmar AM, Zahler S
In preparation.
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